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President’s Perspective
Lisa VanHoose, PT, PhD
President of the Oncology Section;
Department Chairperson and Associate Professor, Hampton University, Hampton, VA
Mahatma Gandhi stated that “the best way to find yourself
is to lose yourself in the service of others.” As you treat your
patients today and tomorrow, take a moment and ask if being a
physical therapist (PT) or physical therapist assistant (PTA) is
a service or a job for you. Your self-assessment will determine
your role as the profession and the Section move forward with
education, policy, research, and outreach initiatives. Service and
employment are not synonymous. A job or employment will
mandate that you continue with the status quo. You will treat
your patients, document, and read just enough research to select
a functional outcome measure and tool for billing. A job is just
that—meeting the employment requirements so that one may
receive money or compensation. Service is more dynamic and
includes passion, courage, and innovation. The PT or PTA who
views the profession as a service contemplates the needs of the
field and the public in the future. He or she seeks out new knowledge to address those needs. He or she has the courage to implement strategies to address the needs. Service requires that we be
an active part of the solution to address the movement needs of
our communities, thereby transforming society.
I strongly believe that an intersection exists between service
and research. Many times, data about the needs of a community
or the generation of ideas or possibilities about an intervention
kindles a flame for a new program, technique, or care delivery
strategy. We also see the opposite, where passion about community needs drives the next research question and project. Research
grants focus on societal impact and innovation. We are encouraged to develop projects across institutions and state lines. Multisite research studies have been utilized for years to improve
recruitment and the impact of the studies. We have been able to
freely enter into these courageous and creative ventures, because
we were not restricted by licensing requirements and practice
acts. We are excited to see this spirit of innovation and possibilities moving into the delivery of physical therapy services.
The Federation of State Boards of Physical Therapy (FSBPT)
began conversations regarding the need for interstate licensure
compacts in 2010. The FSBPT had the foresight to identify that
our licensing processes would be a barrier to accessing physical therapy care. In 2014, the FSBPT Compact Advisory Team
determined that interstate compacts are needed and feasible. The
interstate licensure compact would allow for two or more states
to agree on a “privilege to practice” model in remote states. The
current model recommendation would allow a PT or PTA to hold
an unrestricted license in a primary state and then he/she would
notify remote states, participating in the licensure compacts, of
practice. The notification, and possibly a fee, would allow for
4

“privilege to practice” in remote states. This opportunity would
have immediate impact for many of us providing oncology rehabilitation care. Cancer care is often a shared care model between
academic medical centers, specialized medical care centers, and
community health care centers. Often, our patients travel across
state lines for care due to medical needs or personal factors. The
proposed interstate licensure compacts would allow us to provide
on-site care without the additional burdens of state licensing.
Even more exciting is that interstate licensure compacts would
remove barriers to providing telehealth and telerehabilitation.
It will allow opportunities for many of us to provide essential
services to those who need us most, in rural and underserved
communities. I do believe that each and every one of us will
answer the call to provide physical therapy care with a creative,
passionate, and courageous spirit that can only be described as a
service and not a job. As we serve others, I look forward to each
of us finding ourselves.
Move forward,
Lisa
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Editor’s Message
Lucinda (Cindy) Pfalzer, PT, PhD, FACSM, FAPTA
Editor of Rehabilitation Oncology and Professor (Emerita), Physical Therapy Department,
University of Michigan-Flint, Flint, MI
The lazy days of summer—do we remember when we
thought summer would last forever; but change is inevitable.
There is major news from the Section regarding publication of
the Journal—we have a new publisher beginning January 2016.
Before I get to what this means for the Section and Journal, let me
take a moment to acknowledge the integral role the Orthopaedic
Section has played for our Journal for many years. Sharon Klinski
has been our publisher since 1997 and a large part of the credit for
the quality of the Journal is hers. Thank you Sharon for of all of
your years of dedicated service to the Journal. We appreciate all
of the work that has gone into making the Journal a success. The
decision to change publishers was to bring the Journal into the
multi-media age we now live in. The Journal’s new publisher is
Wolters Kluwer. This publisher will be able to provide improved
access to the Journal in e-reader format, an iPhone app, a searchable portal for members to download individual pdfs of articles
all the way back to the first published issue of the Journal,
an improved webpage and web content for the Journal, and
lastly, increase the reach of the Journal with indexing in OVID.
The Journal is now available electronically through ProQuest,
EBSCO Rehabilitation, Allen Press, and CINAHL. There are
more benefits the members don’t see; but are important for the
quality and work of the Journal such as the electronic manuscript
management system for the authors, reviewers, Associate Editors,
and Editor. I look forward to hearing your feedback next year
specifically regarding the new electronic features of the Journal
as we transition the Journal to multi-media.

Oncology Section

Back to this issue of the Journal, it was a busy first half of
the year with two issues jam packed with research that continues
the focus on evidence for practice. This issue has 4 systematic
reviews from the Section’s EDGE task forces for head and neck
cancer, breast cancer, and prostate cancer. You have an issue full
of information that translates to practice by addressing your needs
to select better outcome measures to improve the examination
and reporting of the care you provide. The Research Round-up
(available via ePub at oncologypt.org/publications/rehabilitationoncology-journal) column reports on the Cancer Rehabilitation
Symposium that was hosted by the Rehabilitation Medicine
Department (RMD) of the National Institutes of Health (NIH)
Clinical Center and was co-sponsored by the National Cancer
Institute and the National Center for Medical Rehabilitation
Research this past June in Bethesda, Maryland. There was lively
discussion, and we look forward to the publication of the working papers and research agenda. Please take a moment to read
about this important initiative. As always, we are open to your
feedback.
Erratum. The authors wish to correct an error in their article
“Recommendations for patient-reported outcome measures
for head and neck cancer-related shoulder dysfunction: A
systematic review” volume 32, issue 3, 2014, p. 10. The statement on the scoring of the NDII should instead read “A lower
score indicates greater impairment.41,46” The authors had this
reversed and we (manuscript reviewers and I) did not catch
it. It was published as “A higher score...” and it should read
“A lower score...”

Celebrate Living

American Physical Therapy Association

2015 ONCOLOGY SECTION SLATE OF CANDIDATES
Vice President
Amy Litterini, PT, DPT
Secretary
Mary Fisher, PT, PhD, CLT
Emily Hemingway, PT, DPT, ATC
Nominating Committee Member
Nancy Paddison, PTA, BA, CLT-LANA
Laura Sheridan, PT, DPT, CLT

Kathy Tasillo, PT, DPT

Go to www.oncologypt.org to View Each Candidate’s Biography Form
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EDGE Task Force on Head and Neck Cancer Outcomes
A Systematic Review of Outcome Measures for
Temporomandibular-related Dysfunction
Mary Lou Galantino, PT, MS, PhD, MSCE1; Melissa M. Eden, PT, DPT, OCS2;
Bryan A. Spinelli, PT, MS, OCS, CLT-LANA3; Ann Marie Flores, PT, PhD, CLT4
Professor of Physical Therapy, School of Health Sciences, Stockton University, Galloway, NJ
2
Assistant Professor of Physical Therapy, Mayo Clinic, Phoenix, AZ
3
Rhode Island Hospital, Rehabilitation Services, Providence, RI
4
Assistant Professor & Director, Center for Cancer Survivorship Studies, Department of Physical Therapy,
Movement and Rehabilitation Sciences, Northeastern University, Boston, MA
1

ABSTRACT
Background: Patients with head and neck cancer (HNC) often
experience significant postoperative limitations in temporomandibular joint (TMJ) function, facial pain, reduced nutritional
intake, speech impairments, and compromised activities of daily
living due to side effects of cancer treatment. Physical therapists
treating these individuals must use valid and reliable patientreported outcome measures to quantify change related to physical therapy intervention for the TMJ. Purpose: As part of the
activities of the Oncology Section EDGE Task Force on Head and
Neck Cancer Outcomes, we report evidence-based recommendations for patient-reported outcome measures for individuals with
HNC-related temporomandibular dysfunction (TMD). Methods:
A systematic literature review of TMD-related patient-reported
outcome measures that are clinically feasible and relevant to
the HNC patient population was conducted using the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) model. Recommendations are based on the quality
of psychometric properties, clinical utility, and previous use
in HNC-related research. Twenty-two outcome measures were
selected for review; 4 received a rating of 3, “recommended” for
use in the HNC population. Conclusions: A variety of outcome
measures have been reported in the literature for individuals with
HNC-related TMD. Four measures, the Graded Chronic Pain
Scale, 8 and 20-item Jaw Functional Limitation Scale and TMD
Pain Screener, are recommended for clinical use by the researchers on this task force although it is important to note psychometric properties specific to the HNC population are lacking.
Systematic Review Registration Number: PROSPERO
CRD42013004898
Address correspondence to: Mary Lou Galantino, PT,
MS, PhD, MSCE, School of Health Sciences, Stockton
University, 101 Vera King Farris Drive, Galloway, NJ 08025
(MaryLou.Galantino@stockton.edu).
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Key Words: temporomandibular, impairment, outcome measure,
head and neck cancer
INTRODUCTION
The incidence of head and neck cancer (HNC) has remained
stable over the past decade due to improvements in the medical
management of the disease, and a 5-year relative survival rate of
60% to 65%.1,2 Treatment for HNC may include a combination of
surgery, radiation, and/or chemotherapy. As of 2012, there were
364,000 HNC survivors in the United States, many of whom
are dealing with the long-term sequelae of HNC treatment.1
The location and nature of the medical management of HNC
places survivors at risk for experiencing temporomandibular
joint (TMJ)-related impairments and disability, which can lead to
temporomandibular joint dysfunction (TMD).2-4
Temporomandibular joint dysfunction is defined as “functional disturbances of the masticatory system.”5 Changes in TMJ,
occlusion, ligamentous, or soft tissue structures, or the muscles
of mastication eventually can result in TMD. The TMJ and masticatory system is complex and requires a comprehensive understanding of the anatomy and physiology of the arthrokinematics,
musculoskeletal, and neurological components in order to treat
TMD. Trismus, restricted mouth or jaw opening, is a form of
TMD that affects 10% to 50% of those with HNC.4,6,7
Radiation therapy for nasopharyngeal, base of tongue, salivary gland, maxillary, or mandibular often affect the TMJ and
associated musculature including the pterygoid and the masseter
muscles.4,8 Loss of TMJ function and range of motion from radiation therapy appear to be related to fibrotic changes to TMJ soft
tissue, including the muscles of mastication.8,9 The HNC postoperative precautions resulting in changes to movement of the TMJ
may also compound emotional aspects and guarding of the TMJ
causing a vicious cycle of reduced movement, pain, and altered
function.8 Trismus in patients with HNC can have serious health
implications, including reduced nutrition due to impaired mastication, difficulty speaking, impaired self-image, ineffective oral
hygiene, and compromised assessments for cancer surveillance.6,8
Rehabilitation Oncology
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DATA & METHODS
This systematic review is registered on PROSPERO
(CRD42013004898). The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) model was
utilized for this systematic review (Figure 1, Appendix 1).18 The
appendices for this article can be accessed via ePub at www.
oncologypt.org
Two investigators (MLG and MME) independently completed
the literature search in April 2014 using Ovid Medline. PubMed,
PEDro, EBSCO Host, PsycInfo, and Cochrane Databases were
Rehabilitation Oncology
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Eligibility	
  

In persons who receive radiation to the head and neck, trismus is
often observed in conjunction with dysphagia.10
A systematic review published in 2014 highlights the
following 12 core domains and symptoms most affected in
HNC survivors: swallowing, oral pain, skin changes, dry mouth,
dental health, opening mouth/trismus, taste, excess/thick mucus/
saliva, shoulder disability/motion, voice/hoarseness, and social
and functional domains.11 It has been reported that individuals
with HNC have a lower quality of life (QOL) than age-matched
controls and in many cases a lower QOL than individuals with
other common cancers.12 However, little research has been
conducted studying TMD in people with HNC that fall within
the scope of physical therapy practice. The few studies related to
TMD in HNC have suggested that pain and restricted motion are
problems experienced by some HNC survivors.3,13-15
Physical therapy assessment must include outcome measures
of physical function, which may include patient-reported outcome
measures (PROs). Despite the risk of TMJ impairments and
disability in the setting of HNC, physical therapists have very
few HNC-specific PROs from which to choose. In fact, a panel
of HNC experts were unable to recommend a PRO specific to
TMD or trismus in the “outcomes toolbox for head and neck
cancer research,” a series of PROs addressing 18 main areas of
concern in the HNC population. The authors only offer an objective measurement for trismus—the interincisal distance.16
When selecting an outcome measure in practice, a physical
therapist must first consider the ability to interpret the test score
in the population of interest. This requires that the psychometric
properties of the outcome measure, such as reliability, validity, sensitivity, specificity, and the ability to detect change, are
available in a population similar to the one of interest. Clinical
utility, the ease of use, and accessibility of needed resources to
administer the measure, are also important factors to consider
when choosing an outcome measure. The Evaluation Database to
Guide Effectiveness (EDGE) initiative by the American Physical
Therapy Association (APTA) is currently identifying core sets of
recommended tests and measures to be used within certain patient
populations and diagnoses.17 The Oncology Section of the APTA
has established task forces for breast, prostate, lung, urogynecologic, and head and neck cancers. The purpose of this systematic
review is to identify and provide recommendations of clinically
feasible and relevant PROs that address pain and function for use
in patients with HNC presenting with TMD.
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Figure 1. PRISMA flow diagram for systematic review
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Figure 1. PRISMA flow diagram for systematic review.

subsequently explored using similar search strategies and terms
(Figure 2). The literature search was limited to human subjects,
availability of an abstract for screening, and publication in the
English language. Because little research on this subject is available, we did not exclude studies based on publication date or level
of evidence. Once duplicates were removed, 1068 total articles
remained for review (Figure 1).
Article titles and abstracts were reviewed, yielding 38 identified PROs. Of these, 22 were chosen for inclusion in the systematic review (Figure 1). To be included in the review, outcome
measures had to be clinically feasible and patient-reported.
Patient-reported outcome measures addressing health related
QOL were excluded unless they were specifically developed
for the HNC population. In addition, questionnaires assessing nonspecific impairment level constructs (ie, visual analog
scale) and other joints/regions not specific to the TMJ region (ie,
Dental Discomfort Questionnaire, 10-item cervical questionnaire,
Sinonasal Assessment Questionnaire) were excluded. Outcomes
specific to HNC that did not contain items related to TMJ function (ie, Cancer Problems in Living Scale, FACT H&N) were
also excluded.
The 22 outcomes were divided between the two investigators for analysis. Relevant studies and full-text articles for each
measure were retrieved to assess the clinical utility, psychometric
properties, and relevance of the PROs to the HNC population.
Clinical utility was based upon cost, ease of use and scoring,
equipment requirements, and availability of normative data.
Ease of use, based on responder burden, and ease of scoring
were characterized as easy, moderate, or difficult. The primary
reviewer completed the Head and Neck Cancer EDGE Task
7

Figure 2. Terms for online database search. Literature search limits included the following: human subjects, English, full abstracts
available.

Force Outcome Measure Rating Form (Appendix 2) for each of
the assigned measures. Recommendations for each PRO were
provided using a rating scale of 1 to 4, where a rating of 1 is not
recommended and a rating of 4 is highly recommended (Table
1). The risk of bias at the study level was not considered when
completing the Rating Form, however, we attempted to decrease
the level of reporting errors through a review by the second investigator. In the case of disagreement between the two investigators,
the rating in question would be brought to the entire HNC EDGE
Task Force for consensus.
RESULTS
After a systematic review of the HNC literature, 22
TMD-related patient-reported outcome measures were identified
for inclusion in this review. The HNC EDGE Task Force recommendations for TMD outcome measures can be found in Table 2.

“Highly Recommended” TMD Outcomes Measures
Of the 22 measures reviewed, no outcome measures merited
the maximum score of 4 and the rating “Highly Recommended.”
The investigators were unable to find a PRO specific to TMD,
which was previously utilized in the HNC research and demonstrates strong psychometric properties and clinical utility.
“Recommended” TMD Outcomes Measures
Four outcome measures received a score of 3,
“Recommended.” These outcome measures include the 8-item
and 20-item Jaw Functional Limitation Scale (JFLS-8, JFLS20), the TMD Pain Screener, and the Graded Chronic Pain Scale
(GCPS). Although no published evidence of the psychometric
properties in the HNC population were found, these measures
have demonstrated good psychometric properties and clinical
utility in other patient populations (Tables 3 and 4).

Table 1. Head and Neck Cancer Rating Scale

8

Highly recommended; the outcome has good psychometric properties and good clinical utility; the measure has been used
in research on individuals with or post head and neck cancer.

4

Highly Recommend

3

Recommend

2A

Unable to Recommend
at This Time

Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure;
the measure has been applied to research on individuals with or post head and neck cancer.

2B

Unable to Recommend
at This Time

Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure;
no published evidence that the measure has been applied to research on individuals with or post head and neck cancer.

1

Do Not Recommend

Recommended; the outcome measure has good psychometric properties and good clinical utility; no published evidence
that the measure has been applied to research on individuals with or post head and neck cancer.

Poor psychometric and/or poor clinical utility (time, equipment, cost, etc)

Rehabilitation Oncology
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Table 2. Outcome Measures Sorted by Task Force Rating
Rating

Measure

3

Graded Chronic Pain Severity (GCPS)

3

Jaw Functional Limitation Scale (8-item version)

3

Jaw Functional Limitation Scale (20-item version)

3

TMD Pain Screener

2A
2A

Late Effects Normal Tissue Task Force/Subjective, Objective,
Management, Analytic (LENT/SOMA)
European Organization of Research Treatment for Cancer Quality
of Life Questionnaire-Head & Neck 35 (EORTC QLQ-HN35)

2A

Liverpool Oral Rehabilitation Questionnaire

2A

University of California San Francisco Oral Cancer Pain
Questionnaire

2A

University of Washington QOL (UW-QOL)

2A

Gothenburg Trismus Questionnaire (GTQ)

2B

Manchester Orofacial Pain Disability Scale (MOPDS)

2B

Subjective Oral Health Status Indicators (SOHSI)

2B

TMJ Scale

2B

TMD questionnaire (LDF-TMDQ, 13 items), Jaw Function Scale

2B

10-item TMJ pain questionnaire

2B

Mandibular Function Impairment Questionnaire (MFIQ)

2B

Modified Symptom Severity Index (Mod-SSI)

2B

Tampa Scale for Kinesophobia

2B

TMD Self-efficacy Scale

2B

TMD Checklist

1

Conti Anamnestic Questionnaire

1

TMD Disability Index

1

TMJ Score Questionnaire

1

Oral Impacts on Daily Performances Inventory

Abbreviations: TMD, temporomandiublar dysfunction; TMJ temporomandibular
joint; LDF-TMDQ, Limitations of Daily Function in Temporomandibular Dysfunction
Questionnaire

The JFLS-20 is a 20-item measure derived through expert
consensus and subsequently validated using Rasch methodologies in a sample of patients with TMD, primary Sjogren
syndrome, burning mouth syndrome, skeletal malocclusion, and
healthy controls.19 It includes 3 subscales (mastication, vertical
jaw mobility, and verbal and emotional expression) and a global
scale of functional limitation of the jaw. The 8-item global scale
of functional limitation of the jaw is known as the JFLS-8. The
JFLS-8 and the JFLS-20 can both be appropriately utilized to
measure TMD dysfunction in clinical and research settings.19,20
Both scales require the patient to rank their level of difficulty on
an 11-point Likert scale, where zero suggests “no limitation” and
a response of 10 suggests “severe limitation.” The recall period

is one month. The total score is calculated by summing the individual item scores, with a higher score indicating greater limitation.19 The JFLS-20 score can range from 0-200 and the JFLS-8
score can range from 0-80.
Internal consistency (Cronbach’s alpha) for the JLFS-8 is
0.87 and for the JFLS is 0.95.19 Test-retest reliability, assessed
through temporal stability and the concordance correlation coefficient, (CCC rho), is 0.81 for the JFLS-8 and 0.87 for the JFLS20.19 An effect size for the JFLS-8 of 0.41 has been reported.20
When analyzed separately, the 3 subscales of the JFLS-20 each
exhibited excellent psychometric properties with respect to
modeled variance, item fit, reliability, and internal consistency
among the 5 diagnostic groups.19 Construct and discriminant
validity have been established through correlations with other
measures, established between-group differences in the subscale
and global functional limitation scores,19 and test score independence from constructs such as depression, somatization, anxiety,
and other clinical findings.20 The JFLS-8 and the JFLS-20 are
also highly correlated (0.9675).19 Neither the JFLS-8 nor JFLS-20
has been used in published HNC research.
The TMD pain screener is a 3-item PRO with a recall period
of the last 30 days. The first item addresses the frequency of pain
(“no pain,” “pain comes and goes,” “pain is always present”). A
response of “no pain” yields a score of zero, “pain comes and
goes” yields one point, and “pain is always presents” yields two
points. The second item addresses pain or stiffness upon awakening, and the third item is a 4-part question assessing a change
in pain level for certain functional activities including chewing, opening/moving the jaw, grinding/clenching, and kissing/
talking/yawning. Item two and the 4 components of item three
have dichotomous response options of “no” and “yes.” A “no”
is awarded zero points and a “yes” is awarded one point. Item
scores are then summed, with a test score of zero to 7 points
possible. A higher score indicates greater limitation. In a population of subjects with pain-related TMD, internal consistency was
deemed excellent (Cronbach’s α= 0.87), and temporal stability
of individual items (κ) ranged from 0.52 to 0.78, indicating fair
to excellent agreement. The summary test score exhibited an
intraclass correlation coefficient of 0.83. The tool was found to
exhibit sensitivity of 99% and a specificity of 97%. The positive
likelihood ratio ranged from 19.2 to 44.6, varying according to
the comparison control group, whereas the negative likelihood
ratio was 0.01 throughout. Both positive and negative likelihood
ratio findings exceeded the accepted benchmarks of 10 or more
and 0.1 or less for the positive and negative likelihood ratios,
respectively. The TMD Pain Screener has not been used in HNC
research.21

Table 3. Clinical Utility for Recommended Outcome Measures
Measure

Equipment Needed

Cost

Ease of Use

Scoring

Normative Data

JFLS-8/ JFLS-20

Outcome measure, pen

Free

Easy

Easy

Not available

TMD Pain Screener

Outcome measure, pen

Free

Easy

Easy

Not available

Graded Chronic Pain Scale

Outcome measure, pen

Free

Easy

Moderate

Not available

Abbreviations: JFLS, Jaw Functional Limitation Scale; TMD, temporomandibular dysfunction
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Table 4. Psychometric Properties for Recommended Outcome Measures
Outcome Measure
Graded Chronic Pain Severity
(GCPS)

Psychometric Properties
Internal consistency (Cronbach’s alpha):
Characteristic Pain Intensity Measure α = 0.84
Interference Measure α = 0.95
Temporal stability:
Characteristic Pain Intensity CCC = 0.91
Interference Measure CCC = 0.89
Convergent and discriminant validity of characteristic pain intensity was supported by a substantial association with
MPI pain severity (CCC = 0.65) and smaller associations with measures of constructs other than pain (eg, depression
[CES-D], somatic symptoms). Such validity was supported for interference by substantial associations with the MPI
interference (CCC = 0.52) and dysfunctional measures (CCC = 0.51), and by smaller associations with measures of other
constructs (eg, the SF-12, CES-D).23
Sensitivity to change not tested.

TMD Pain Screener

Internal reliability α= 0.87
Temporal stability of the individual items (κ) ranged from 0.52 to 0.78, indicating fair to excellent agreement.22
Summary score ICC= 0.83
Validity for TMJ-related pain:
Sensitivity= 99%
Specificity= 97%
Researchers deemed the content validity to be excellent.
Sensitivity to change not tested.

Jaw Functional Limitation Scale
(JFLS versions 8 and 20)

Construct validity was established via low correlations with depression, anxiety, somatization, pain interference, painfree opening, and palpation sensitivity, and via moderate correlations with pain and jaw symptoms.20
Internal consistency (Cronbach’s alpha):
JFLS-8 - α = 0.87
JFLS-20 - α = 0.95
Temporal stability19:
JFLS-8 CCC= 0.81
JFLS-20 CCC= 0.87
Sensitivity to change not tested.

Abbreviations: CCC, concordance correlation coefficient; MPI, Multidimensional Pain Inventory; CES-D, Center for Epidemiological Studies-Depression Scale; SF-12,
Short Form-12, TMD, temporomandibular dysfunction; TMJ, temporomandibular joint

The GCPS (version 2.0) is an 8-item PRO. In general, symptom recall is for the last 30 days; however, one item has a 24-hour
recall and another item has a 6-month recall period. Six of the
items are scored on an 11-point Likert scale, with a response
of zero indicating no interference or pain and a response of 10
indicating “pain as bad as could be” or “unable to carry on any
activities.” Item one requires the patient to report the number of
days the patient experienced facial pain in the past 6 months, and
item 5 requires the patient to report the number of days facial pain
limited performance of usual activities in the past 30 days. Scores
are calculated for 3 subscales: the characteristic pain intensity
score, which ranges from 0–100, is calculated as the mean
intensity ratings for reported current, worst, and average pain;
the disability score, which ranges from 0–100, is calculated as
10

the mean rating for difficulty performing daily, social, and work
activities; and the disability points score, which ranges from 0–3,
is derived from a combination of ranked categories of number
of disability days and disability score. Subscale scores for pain
intensity and disability are combined to calculate a chronic pain
grade that enables classification of chronic pain patients into 5
hierarchical categories: grades 0 (no pain) to IV (high disabilityseverely limiting).22
The GCPS is a reliable and valid instrument that assesses
the constructs of pain intensity and pain-related disability. The
measure’s psychometric properties were studied in a population
of patients with back pain, headache, and TMJ disorders. The
internal consistency was measured with Cronbach’s α = 0.84
for the pain intensity subscale and Cronbach’s α = 0.95 for the
Rehabilitation Oncology
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pain-related disability subscale. The temporal stability (2–7 days)
was high for pain intensity (CCC = 0.91), pain-related disability
(CCC = 0.89), and chronic pain grade (weighted kappa = 0.87).22
Among patients with moderate to severe chronic musculoskeletal
pain, the GCPS has been shown to be modestly responsive to
changes after 12 months of treatment with an efficacious pain
intervention, with standardized moderate effect sizes for the
intensity and disability sub-scales of 0.41 and 0.43, respectively.
Among participants with chronic knee or hip pain, the standardized effect size for the GCPS intensity was 0.32.23 The GCPS has
not been used in HNC research.
“Unable to Recommend at This Time” TMD Outcomes Measures
Sixteen outcome measures received a score of 2 and are not
recommended at this time for use by physical therapists treating individuals with TMD in the setting of HNC. A score of 2
is further categorized as 2A if the measure has been used in the
HNC literature or 2B if there is no published evidence that the
tool has been used in HNC-related research. Six PROs were
designated a rating of 2A, including the EORTC QLQ H&N43,24
University of Washington Quality of Life (UW-QOL),25,26
Liverpool Oral Rehabilitation Questionnaire version 3 (LORQ),27
University of California San Francisco (UCSF) Oral Cancer Pain
Questionnaire,28 the Gothenburg Trismus Questionnaire (GTQ),29
and the Late Effects in Normal Tissues Subjective, Objective,
Management and Analytic Scales (LENT/SOMA).30
Two HNC-specific QOL measures were included in the
review, the EORTC QLQ H&N 43 and the UW-QOL. The
EORTC QLQ H&N43 is the most recent revision of the EORTC
QLQ-H&N 35. It currently lacks psychometric studies to support
its use. More importantly, similar to the UW-QOL, the EORTC
QLQ-H&N43 is a measure designed to quantify health-related
QOL and therefore provides a test score interpreted as an overall
QOL score for many constructs, not a score specific to TMD. As a
result, these two HNC-specific QOL measures cannot be recommended solely for quantification of TMD dysfunction.
The LORQ is a 40-item measure developed through expert
opinion. It addresses issues related to oral function, oro-facial
appearance, social interaction, and dentures/dental prostheses.
While the tool is relevant to the HNC population, it lacks strong
psychometric properties and easy accessibility to scoring and
interpretation. In addition, over half of the questions pertain
to oral prosthetics, therefore decreasing its utility for a large
portion of the HNC population.27 The UCSF Oral Cancer Pain
Questionnaire is an 8-item PRO used to quantify patients’ pain
levels before and after surgical resection for oral cancer. Items
one, 3, and 5 evaluate the intensity, sharpness and throbbing
nature of pain when the patient is not engaged in oral function.
Items 2, 4, and 6 measure the intensity, sharpness, and throbbing
nature of pain during oral function (talking, eating, and drinking).28 Although some of these items are related to TMJ function, this tool is not specific to TMD and has not been validated
for patients with TMD. In addition, the measure is not easily
accessible to clinicians. The GTQ is the only measure reviewed
Rehabilitation Oncology
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specifically designed to measure trismus.29 Unfortunately, the tool
is not easily accessible and lacks supporting research. The LENT/
SOMA scale addresses radiotherapy toxicities in patients with
HNC and is therefore not relevant for use by physical therapists.30
Ten PROs reviewed received a 2B rating, including: Subjective
Oral Health Status Indicators (SOHSI),31,32 10-item TMJ Pain
Questionnaire,33 Mandibular Function Impairment Questionnaire
(MFIQ),34 Modified Symptom Severity Index (SSI),35 TMD
Checklist,36 TMJ Scale,19 TMD Questionnaire (LDF-TMDQ),
which is also known as the Jaw Function Scale,37 the Manchester
Orofacial Pain Disability Scale (MOPDS),38 Tampa Scale for
Kinesiophobia,39 and the TMD Self-efficacy Scale.40
Although the SOHSI, 10-item TMJ Pain Questionnaire,
MFIQ, Modified SSI, and TMD Checklist may appropriately
measure the construct of TMD dysfunction, the questionnaires
and information on scoring and interpretation are not easily
accessible by clinicians and therefore cannot be recommended.
The TMJ Scale is, however, accessible to clinicians, but at a
financial cost. It is also 97-items in length and therefore not
feasible for use in a busy clinical setting.19 Our review also found
that the LDF-TMDQ and the MOPDS have been developed in
other countries and may lack validity in the United States. Two
PROs, Tampa Scale for Kinesiophobia, and TMD Self-Efficacy
Scale, may be of benefit for use in a holistic assessment of TMD,
however, do not specifically address the construct of TMD and
therefore cannot be recommended at this time.
“Not Recommended” TMD Outcome Measures
Four outcome measures were given the lowest score of 1
and are not recommended secondary to limited to no available
research supporting the psychometric properties of the tools
across all patient populations. These outcome measures include
the Conti Anamnestic Questionnaire,41 the Oral Impacts on Daily
Performance,42,43 TMD Disability Index,44 and the TMJ Score
Questionnaire.45
DISCUSSION
The APTA’s Oncology Section Head and Neck EDGE Task
Force recommends that physical therapists use the GCPS, JFLS-8
or JFLS-20, and/or the TMD Pain Screener to quantify TMD in
patients with HNC. These measures merited a score of 3, “recommended,” because they demonstrate good psychometric properties, but have not been tested or utilized in HNC literature. Each
of the recommended measures can be found in the Diagnostic
Criteria for Temporomandibular Disorders (DC/TMD), which is
a compilation of clinical and patient-reported measures designed
to assess TMD in clinical and research settings.46 The DC/TMD
has two components, Axis I and Axis II. Axis I of the DC/TMD
includes the TMD Pain Screener, a symptom questionnaire, demographics, and a clinical examination. Axis II includes various
PROs addressing constructs related to QOL, anxiety, depression,
and TMD, including the JLFS-8, JLFS-20, and GCPS.47
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Only 6 of the 22 measures reviewed in this study have been
used in the HNC literature, all of which were not recommended
at this time due to concerns regarding tool accessibility, clinical
utility, test score interpretation specifically for TMD dysfunction, and availability of psychometric data to merit their use.
Given the lack of PROs related to TMJ dysfunction designed
for the HNC population, physical therapists are left to use
TMJ-related outcome measures that have been designed for other
patient populations whose needs may be quite different than the
particular concerns of a patient with HNC. Additional research
is therefore required to determine the psychometric properties of
the measures recommended by the HNC EDGE Task Force in the
HNC population, and to further study relevant PROs that could
not be recommended by the Task Force at this time. For example,
the TMD Disability Index is similar in format to the Oswestry
Disability Index and Neck Disability Index, both frequently used
PROs in the physical therapy profession for back and neck pain,
and has been used in physical therapy research.48-51 Despite its
use, the TMD Disability Index received a rating of “not recommended” because psychometric properties for the measure have
not been reported.
A systematic review of the literature to identify publications
utilizing PROs suitable for oral and maxillofacial surgery found
there are numerous questionnaires available, however selecting
the most appropriate one can be difficult.52 Ojo and colleagues53
explored HNC QOL instruments and determined that crossstudy comparisons have been hampered by the heterogeneity
of measures used in research and the fact that reviews of HNC
instruments have not been comprehensively studied. Given the
volume and heterogeneity of PROs there is no gold standard
HNC-specific TMD questionnaire.53
Similar to the Oncology Section’s HNC EDGE Task Force’s
reviews on neck and shoulder PROs and measurement of external
lymphedema for HNC survivors, 54,55,58 the obvious limitation in
this review, was that very few of the measures reviewed have
actually been utilized to evaluate TMJ-related impairment and
disability in the HNC patient population. Referral to physical
therapy for HNC related-TMD is underutilized.56 In addition,
there are a limited number of investigators with expertise in
TMJ-related impairments and function conducting research in the
HNC population. Prolonged survivorship due to improved medical management of HNC increases the importance of restoring
optimal function in order to improve QOL and function.56 Given
the rise in HPV-associated HNCs, improvements in early detection, prevention, and medical management strategies, patients
with HNC may have unmet physical therapy needs to reduce or
prevent TMJ disability.
To our knowledge, this is the first attempt at providing recommendations for TMD-specific PRO utilization by physical therapists treating patients with HNC. Future research should consider
the psychometric properties of PROs, including establishment of
normative values and responsiveness to change, addressing TMD
in the HNC population. Although great strides have been made in
the assessment of PROs and QOL in HNC, more work is needed
12

to improve the clinical utility of these measures in order to link
research to clinical practice.9,53,57
CONCLUSION
The HNC EDGE Task Force recommendations provide
physical therapists with evidence-based outcomes measure
recommendations for use with patients with HNC presenting with
TMD. The HNC EDGE Task Force recommends 4 measures that
are easy to use in the clinic with good psychometric properties.
These measures fulfill Medicare functional outcome reporting
requirements and can provide reliable and valid data from which
to quantify patient response to physical therapy interventions.
Our review reveals a gap in psychometric research evaluating properties of available TMJ-related PROs applied in the HNC
population. The HNC EDGE Task Force reviews include recommendations for other areas that affect HNC patients that fall under
the scope of practice for physical therapy such as neck,54 shoulder,55 and lymphedema.58 Further research is needed to evaluate
psychometric properties of PROs for use in the HNC patient
population. Studies evaluating HNC-specific PROs’ responsiveness to change, generation of normative values, and reliability
and construct validity in the HNC patient population are needed.
The HNC EDGE Task Force recommendations are a first-step to
fill the gap in knowledge of useful, relevant, and patient friendly
TMJ-related outcome measures for the HNC patient population.
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ABSTRACT
Background: Survivors of head and neck cancer (HNC) and
its treatment experience high rates of lymphedema. Unlike the
extremities, the head and neck is difficult to measure and does
not easily lend itself to having a contralateral side for comparison.
Being an irregularly shaped part of the body, measures of edema
for the extremities cannot be adapted for the head and neck. The
need exists for outcome measures to objectively quantify head
and neck lymphedema using evidence-based practice guidelines.
Purpose: The purpose of this study is to identify and recommend external edema outcome measures for lymphedema in the
HNC population. Methods: A systematic review of the literature on edema measures for use in the HNC patient population
was conducted. The Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) model was used to
guide which articles were chosen for inclusion, determination
of eligibility, screening, and identification for the final review.
Recommendations are based on the quality of psychometric
properties, clinical feasibility, and previous use in HNC-related
research. Six edema outcome measures were reviewed and none
are recommended at this time; however, several hold great promise for future use in the clinic. Conclusions: This systematic
review provides an overview for physical therapists on measures
of external edema for the HNC patient population. The edema
measures included in this review have been tested on HNC
patients but have not been rigorously tested due to their novelty.
At this time, no outcome measures for objectively quantifying
external edema for the HNC population can be recommended.
There is need for more research on this topic prior to providing
definitive recommendations.
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INTRODUCTION
Cancers of the head and neck (HNC) involve the oral cavity,
pharynx, larynx, paranasal sinuses, nasal cavity, salivary glands,
upper esophagus, face, associated musculature, and/or bone and
some thyroid cancers.1 Head and neck cancer represents 3% of
all cancer survivors in the United States and is considered an understudied tumor type.2 The 5-year relative survival rate of these
cancers widely varies—94% (lip cancer), 74% (salivary gland),
and 30% (hypopharynx, and “other” cancers of the oral cavity
and pharynx)2 with approximately 291,108 people living with oral
cavity and pharyngeal cancers in the United States in 20123– likely an underestimate since laryngeal, thyroid, and upper esophageal cancers are also head and neck cancers.3,4 Despite the rarity of HNC, disability and other side effects are highly prevalent.
Lymphedema is known to affect the majority of HNC survivors
(60-80%) affecting external structures (eg, outward and obvious swelling of the neck, head, and face), internal structures (eg,
tongue, oral cavity, pharynx, hypopharynx, larynx, trachea, and
esophagus), or a combination of both.5,6 Head and neck cancer
survivors usually have one or multiple treatment modalities. For
example, tumor and lymph node resection and/or radiation, chemotherapy, or combined chemotherapy and radiation (CCR).7,8
These treatments can be a grueling experience with serious side
effects (eg, mucositis, cachexia, fatigue, oral and non-oral pain)
that may require feeding tube placement.9
Location of the tumor, tumor and lymph node resection, radiation, and multiple modality treatment are all associated with
lymphedema of the head and neck.5 Other posttreatment factors
such as muscle guarding, abnormal posture, and reduced movement in the affected areas may also contribute to lymphedema
among HNC survivors.10 Lymphedema, left untreated, can have
serious consequences resulting in risk for recurrent infection such
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as cellulitis, and interference with the ability to breathe, swallow,
and/or speak—key functions of life.6
The 5-year relative survival rate from HNC, particularly for
those with human papillomavirus (HPV) positive tumors, is improving. Survival rates (relative and absolute) are high. For example, survival rates for oral cavity and pharyngeal tumors are
62.7% and for laryngeal cancers, 60%. With increased survival,
it stands to reason that more HNC survivors will be living with
long-term cancer-related lymphedema.6,12 Head and neck cancer
survivors diagnosed with lymphedema are commonly referred to
physical therapy for lymphedema management.13,14 Complete assessment of lymphedema involves patient subjective complaints,
physical examination (ie, pitting, tissue texture), and objective
tests and measures.15-17 Reliable and valid measures are necessary
for clinicians to accurately assess and document patient progress
and guide clinical decision-making.
This systematic review is part of the Evaluation Database to
Guide Effectiveness (EDGE) activities of the American Physical
Therapy Association Oncology Section’s Head and Neck Cancer
Task Force. The purpose of this systematic review is to identify
and provide recommendations of clinically feasible and relevant
objective tests and measures of edema for HNC survivors with
cancer-related lymphedema.
DATA & METHODS
The authors registered this systematic review on PROSPERO
(CRD42013004898). The search was limited only to studies that
report on measurement of edema due to cancer treatment-related
lymphedema of the head and neck. Because little research exists
on concerns of HNC survivors that falls within the scope of
physical therapy practice, we placed no limits on publication
dates or level of evidence. We conducted a search of literature
databases (PubMed, PEDro, EBSCO Host, Medline, PsycInfo,
and Cochrane Database) using the following key words in all
combinations: edema, human, lymphedema, cancer, head, neck,
radiation, radiotherapy, surgery, neck dissection, face, measurement, outcome, outcome measure, radiation fibrosis, lymphostasis, inflammation, reliability, and validity. Articles were limited
to studies on humans and published in English. Duplicates were
removed and abstracts for all citations were screened to determine
if they were to be included in the final review. Figure 1 illustrates
the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) process used for the literature search.
Two investigators (AMF and BAS) independently completed
a search of the literature using the databases and personal files
of published articles not included in the literature databases as
mentioned earlier in June 2014. This provided verification of the
search results. The investigators then independently reviewed
the abstracts of the search results and eliminated non-relevant
articles based on the predetermined inclusion criteria (English
language, any date of publication, any level of evidence) and
exclusion criteria (no requirement of a physician prescription or
performance of a medical procedure for measuring edema, nonhuman sample, quality of life study). The measures of edema
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Figure 1. PRISMA model.

identified by the authors were divided between reviewers, who
independently retrieved relevant studies and full-text articles for
each measure to assess clinical feasibility, psychometric properties, and relevance to the HNC patient population. The primary
reviewer completed the HNC Task Force Outcome Measure
Rating Scale Form (Table 1) for each assigned measure. The
risk of bias of measure assessment was addressed by ensuring a
secondary review for all measures. In the case of a discrepancy
in rating between reviewers, two other investigators were available to evaluate the reviews and determine the decision outcome,
along with the other two investigators, until total agreement was
reached. Outcome measure recommendations were agreed upon
using the EDGE criteria resulting in an ordinal score with anchors
at 1 (measure is not recommended) and 4 (measure is highly
recommended) (see Table 1).18
RESULTS
Using our keywords, we identified 25,007 records. All
duplicates were removed which resulted in 11,337 articles.
Eighty-six outcome measures of lymphedema were identified;
40 were patient reported outcomes (PRO) (represented in 141
articles) and the remainder were clinical measures (represented
in 254 articles). We excluded 46 measures which had only one
article addressing the measure. Using the remaining articles, the
investigators generated a list of 12 measures of edema for HNC
treatment-related lymphedema. Of these clinical measures, only 7
represented measurements of external edema for lymphedema of
the head and neck that can be performed by physical therapists:
real-time ultrasound, 3-dimensional (3D) laser scanning, tissue
dielectric constant (TDC) method, M.D. Anderson Cancer Center
– head and neck lymphedema rating scale (MDACC-HNLRS),
and the ALOHA method (circumferential volume revised for
head and neck), frustum volume estimation, and disk model
method. One hundred thirty-nine references were included in the
review (see Figure 1 and Table 1).
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“Highly Recommended” and
“Recommended” Edema Outcome Measures
In order to reach this level of recommendation, the measure
must have evidence supporting excellent psychometric properties
and clinical utility. The measure should also have been tested in
the HNC population. Of the 6 measures, none reached the level of
“highly recommended” or “recommended,” per the requirements
outlined in Figure 2.
“Unable to recommend at this time”
Edema Outcome Measures
This recommendation has two levels depending on whether
the measure has been used in the HNC patient population (2A)
or not (2B). Four types of measures reached this level of recommendation. Three of these use technological devices to measure
external edema—ultrasound, 3D scanning, and TDC. The final
type is standardized tape measurement of the head, neck, and
face. Included in this final type are two different approaches—the
MDACC-HNLRS and the ALOHA tape measurement system. All
have been used in the HNC population.
Real-time ultrasound measures skin-to-bone distance, skin
thickness, subcutaneous thickness, and/or resistance to compression. Measurement of skin to bone distance at the mandibular
ramus, angle and hyoid using a 7.5 MHz linear transducer was
found to be reliable in healthy individuals (intraclass correlation coefficients ICC, ranged from 0.88 to 0.97).14 Skin thickness (r = 0.95) and subcutaneous thickness (r = 0.84) have been
shown to be strongly correlated with duration of lymphedema in
women with breast cancer-related lymphedema.19 At the time of
this writing and to the best of our knowledge, no studies have
formally investigated the responsiveness of ultrasound as a
measure of edema among those with HNC-related lymphedema.
However, one study showed a significant reduction in skinto-bone distance after patients with HNC-related lymphedema
received a course of manual lymphatic drainage and compression
therapy.14 Significant differences in skin thickness were found in
patients who received systemic enzyme therapy after undergoing
bimaxillary orthognathic surgery compared to those who did not
receive systemic enzyme therapy.20

Three-dimensional scanning is a more recent application
in its use for edema measurement. It has been used in a variety of industries—engineering where it is used for design and
building projects;21,22 forensics where it is used to estimate size,
volume, and topography of missing body parts;23,24 manufacturing where it is used for machining;25,26 and dentistry where it is
used in the creation of dental implants and dentures.27,28 Threedimensional scanning uses laser technology to scan the body part
to be measured. It is a noninvasive approach with no radiation
exposure and excellent reproducibility, with an error of less than
one tenth of a millimeter.29-31 However, Harrison et al reported a
measurement error range between 0.3-4.0 cm3 largely attributed
to changes in positioning.32 The sensitivity33 and reliability29-40
of this method of edema measurement are high. Ramos and
colleagues33 report that 3D imaging is sensitive, reproducible, and
significant in detecting change in those with breast cancer-related
lymphedema with initial volumes of 500 mL or less. The mean
error of measurement for volume measured using 3D imaging
has been found to be within 3.5%.39 Kau et al40 measured facial
morphology in 473 male and female subjects using this technology. The average linear distance among male subjects ranged
from –6.30 to 4.44 mm, with similar measurements among
females ranging from –6.32 to 4.25 mm.40 Together, these studies provide reference values for comparison for future studies.
Limited research33,39,40 using this method in the HNC survivor
population exists at this time. However, this method allows one
to measure any linear distance from any point to another in the
affected and unaffected areas.
Like the 3D scanning technique, the TDC has also been used
in health research and other industries. The Moisture Meter D
(Delfin Technologies, Kuopio, Finland), is the only TDC device
that has been tested with HNC survivors to measure cancerrelated lymphedema. Inter-observer reliability, measured by the
ICC has been found to be 0.973 in previous research.41-43 Internal
consistency has not been reported nor has the measurement error
for the head and neck. The TDC device measures physiologic
properties of biological fluid to a depth of between 0.5 mm – 5
mm for the ventral forearm and 2.5 mm on the lateral thorax.
These depths not only vary by body location but also depend on

Table 1. EDGE Head and Neck Cancer Task Force Outcome Measure Rating Form
EDGE Head and Neck Cancer Task Force Outcome Measure Rating Form
4

Highly Recommend

The outcome has excellent psychometric properties and clinical utility; the measure has been used in research on individuals with or post head and neck cancer.

3

Recommend

The outcome measure has good psychometric properties and good clinical utility; no published evidence that the measure
has been applied to research on individuals with or post head and neck cancer.

2A

Unable to Recommend
at this time

There is insufficient information to support a recommendation of this outcome measure; the measure has been used in
research in individuals with or post head and neck cancer.

2B

Unable to Recommend
at this time

There is sufficient information to support the recommendation of this outcome measure; no published evidence that the
measure has been applied to research on individuals with or post head and neck cancer.

1

Do Not Recommend
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Poor psychometrics &/or poor clinical utility (time, equipment, cost, etc).
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the diameter of the probe used for TDC.41 Recently, the TDC has
been tested on the forehead and just below the maxilla (cheek)
to measure the TDC up to a depth of 0.5 – 2.5 mm, but the
thickness of the skin was a mediator in the measurement. This
means that as tissue thickness increases in the forehead, the TDC
value is reduced, but the opposite is true for the maxillary TDC
measurement. However, in general, as tissue thickness increases,
so does the TDC value indicating increased water content.44 Only
a few studies have used this method with HNC survivors, but it
has not yet been tested for safety, efficacy, diagnostic reliability,
and validity with large samples. Nixon et al45 report interrater
reliability as 0.97. They also report that the TDC, as measured
by the Moisture Meter D, was able to discriminate between HNC
survivors and healthy controls (t = 8.97, p < 0.001). The TDC
was also correlated with linear tape measurements of the head
and neck area (rho = 0.37-0.38), but not with the rating scale used
by the MDACC-HNLRS. This study used a small sample size of
40—20 HNC survivors and 20 healthy controls.43 At the time of
the writing of this paper, this device is experimental in the United
States in terms of its application in assessing edema of the head
and neck. Unfortunately, none of the studies examined for this
review considered obesity or tissue fibrosis as possibly leading to
inaccurate estimates of fluid in the head and neck.
The tape measurements are based on dental and maxillofacial surgery measurement standards first described by Gabka et
al46 and later modified by Schultze-Mosgau et al.47,48 Both were
further adapted by Smith and Lewin to include neck measurements used in the MDACC-HNLRS.17 The facial measures rely
on the use of bony landmarks of the face and head.17,43,44 Both
MDACC-HNLRS and the ALOHA approach use linear distance
measures. The MDACC-HNLRS uses 12 measures adapted from
Gabka et al.46 Two are point-to-point measures (mandibular angle
to angle and tragus to tragus), 7 are facial measures (tragus to
mental protuberance; tragus to mouth angle; mandibular angle
to nasal wing; mandibular angle to medial canthus; mandibular
angle to lateral canthus; mental protuberance to medial canthus;
mandibular angle to mental protuberance), and 3 are circumferential neck measures (superior neck immediately beneath the
mandible; medial neck midway between the superior and inferior
neck; inferior neck at the base of the neck).17,46 The ALOHA
tape measurements utilize one point-to-point measure (ear to ear
beginning at the inferior ear lobe/face junction of the left and
right meeting at a point 8 cm inferior to the lower lip); 3 circumferential measures (lower neck circumference at the base of the
neck; upper neck circumference inferior to the mandible; length
from lip to lower neck circumference along the midline inferior
lower lip to lower neck circumference). Purcell et al43 compared
3 measurement methods—MDACC-HNLRS, ALOHA, and TDC
alone. The ALOHA trial showed high interrater reliability for 3
tape measures with ICCs ranging from 0.948 (ear to ear length),
0.969 (upper neck circumference) and 0.979 (lower neck circumference).43 The only tape measurement found not to have high
interrater reliability was the lip to lower neck circumference
length (ICC = 0.420).43 Unlike the TDC, tape measures did not
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significantly discriminate between HNC survivors with lymphedema and healthy controls.43 However, the authors recommend
the tape measures as sensitive enough to measure within-person
change over time, but did not provide evidence to support this
claim.43 Moreover, from a practical perspective, tape measurement takes a great deal of time to perform, making it difficult
to measure irregularly shaped parts of the face and head such as
the edema in the mandibular, auricular, nasal, orbital and submandibular areas. Table 2 provides a summary of the psychometric properties of these measures.
“Not Recommended” Edema Outcomes Measures
The remaining two measurements—frustum and disk model
methods—merited a score of “not recommended.” This means
that poor psychometrics and lack of clinical utility exists for the
frustum and disk model methods. Both of these edema measures
were tested together in the studies we examined; however, it is
important to note that each is a distinct method. The frustum
method is an ancient method used to estimate the volume of
multi-sided pyramidal shapes. A frustum is a geometric solid
volume measurement of a cone or pyramidal structure and is
created by at least two planes that bisect one another to form a
side of a cone. In contrast, the disk method relies on the sum of
multiple circumferential measures of a cone. Both methods are
ideal for conical measures, and therefore, have been limited to
use in the extremities.48,49 An exception to this is one study that
used a sample of 4 patients with head and neck lymphedema, in
which the frustum method was calculated based on circumferential tape measurements of the head.50 The frustum and disk model
methods have also been used to measure volume of the prostate—
another irregularly shaped body part. The frustum method was
found to underestimate prostate volume by 50% when compared
to planimetry and overestimated volume compared to ultrasound
guided MRI.45 While these methods are useful for the extremities, only the frustum method has been used on a small sample
of HNC survivors50 at the time of this writing. Unfortunately, no
psychometric data are reported for the HNC patient population
using these measures (see Table 2).
DISCUSSION
While smoking and/or alcohol abuse are common causes of
HNC,1 specific types of HPV cause nearly 32% of all HNC cases
and this incidence is expected to rise.12 With this growth, we expect that physical therapists will experience increased referrals for
patients with HNC. In addition to lymphedema, HNC survivors
undergoing treatment will have reduced dietary intake, with 37%
to 68% experiencing moderate to severe pain, impaired swallowing, xerostomia, taste, and hoarseness.52 Conical measures using
circumferential measures or formulae dependent on circumferential measures (eg, frustum, disk model methods) are easy to use
to measure edema of the extremities, but they do not adequately
measure edema in the head and neck. These methods may underestimate volume of the head and neck.51 Aside from surgical
anatomy changes and associated side effects, the addition of side
Rehabilitation Oncology
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Table 2. Psychometric Properties and Clinical Utility of External Edema Measures
Measure

Rating

Relevant Psychometric Properties
Test-retest reliability14
ICC = 0.88-0.97

Ultrasound

2A

Clinical Utility
Intensive training is required. Equipment (ultrasound unit) is
costly, but is becoming more readily available in physical therapy
clinics due to usage with musculoskeletal conditions. However, a
higher frequency probe is typically used to measure skin thickness.

SEM: 0.50-0.64 mm
MDC95%: 1.37 – 1.78 mm
MCID, reference values: NA
Mean coefficient of variation for volume29
2.02 – 5.09%

Three-dimensional
Scanning

2A

Intensive training is required. Equipment (3-dimensional imaging
system) and computer software is costly and not readily available
in clinic. Requires standardized patient positioning.

Mean error29,30,34
0.31 – 0.86 mm
0.01 – 0.23 cm3
SEM, MDC, MCID: NA
Reference values40
·
Males: –6.30 to 4.44 mm
·
Females: –6.32 to 4.25 mm
Interrater reliability43
ICC: 0.42 – 0.95

Tape Measurement

2A

Concurrent validity with Moisture Meter43
r = 0.17 –0.38, p > 0.05 for all measurements
except lip to lower neck circumference

Easy to use. Minimal training required. Equipment (tape measure)
is inexpensive and readily available. Requires standardized patient
positioning.

SEM, MDC, MCID, reference values: NA
Intrarater reliability43
ICC: 0.97
Tissue Dielectric
Constant

2A

Easy to use. Minimal training required. Equipment (Moisture
Meter™) is costly and not readily available in clinic.

Interrater reliability43
ICC: 0.97
Concurrent validity with MDACC level 43
r = 0.58
SEM, MDC, MCID, reference values: NA

Abbreviations: ICC: intraclass correlation coefficient; SEM: standard error of measure; MDC: minimal detectable change; MCID: minimal clinical important difference;
NA: not available; MDACC: MD Anderson Cancer Center Head and Neck Lymphedema Rating Scale

effects associated with chemotherapy, radiation, or CCR increases
the risk of lymphedema of any of the structures targeted by cancer
treatment. For example, radiation-induced tissue fibrosis will include damage to the remaining lymphatic structures in the treated
area.54
Subjective information through self-reports such as heaviness, tightness, and firmness5,6 along with objective information
provided by clinical measurement of lymphedema can provide
information to determine successful outcomes when treating
HNC survivors. Lymphedema is a multi-faceted diagnosis based
on the presence or absence of skin integrity, color, edema, pitting, positive Stemmer’s sign, and malformations associated with
lymphostasis and infection.15 Therefore, using edema measurement as a singular indicator of lymphedema can be misleading
in determining the severity of the lymphedema.16,55 However, in
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the head, face, and neck, edema drastically changes one’s appearance and may impair the ability to breathe, swallow, and vocalize,
making external measures of edema a crucial part of any physical therapy examination, evaluation, and assessment of the HNC
survivor. It is important that physical therapists treating the HNC
survivor with lymphedema have reliable and valid measures of
edema that are clinically feasible and have realistic and reasonable associated costs. While there are also internal measures of
lymphedema, these are invasive and require technical procedures
that fall outside of the scope of physical therapist practice. For example, a bronchoscopy is performed by an otolaryngologist to assess internal swelling as well as check for cancer recurrence in the
oropharyngeal cavity, as Deng and colleagues have done. Bronchoscopy is not risk-free. These risks include aspiration, vocal
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cord damage, bleeding, oxygen desaturation, bronchospasm, fever, pneumonia, pneumothorax, and death.56,57 Physical therapists
specializing in HNC would benefit from having well-formed relationships with physician or speech therapy practitioners to take
advantage of information resulting from imaging procedures outside the PT scope of practice. Additional measurements could be
taken and internal and external volume could then, hypothetically,
be calculated. Three-dimensional scanning, ultrasound, and TDC
can be performed by physical therapists; however, each require
additional training on the use and application of these methods.
Three-dimensional scanning has a steep learning curve because it
requires that the user know how to use the scanner and requires
multiple images to render a 3D image. The software to create
these images is complex and difficult to learn. Further, the cost of
a 3D scanner, software and software training is cost-prohibitive
for the average clinical setting. Real-time ultrasound, on the other
hand, is increasingly utilized in physical therapy clinics and those
who already use it for evaluation of treatment of patients (such as
urinary incontinence or adhesive capsulitis) may find it easy to
use in the HNC patient population. Finally, TDC appears to be the
easiest to use, set-up, and interpret.
Quantifying edema reduction is crucial to gauge the effect
of treatment for lymphedema in the head and neck. It presents a
unique measurement challenge in effectively treating HNC survivors. Edema measurement will fulfill new Medicare outcomes
documentation requirements to demonstrate reduction in volume
due to external lymphedema. At this point, there is no gold standard to measure edema in the head and neck. Common practice
involves linear distances of the face and circumferential measures of the neck—such as those used in the MDACC-HNLRS
and ALOHA methods. However, neither of these methods actually measure volume but provide a way to document reduction in
linear distance that is reasonably expected to reflect a reduction
in volume in response to treatment. The advantage of the linear
distances used in these measures is that clinically speaking the
baseline of these measures could be measured using diagnostic
MRI or CT scan. However, this approach involves the cooperation of physicians—particularly radiologists—and is not typically
measured as part of clinical standards of care. Another advantage
of the MDACC-HNLRS and ALOHA methods is that both provide a systematic way to measure edema. The ALOHA method
also incorporates measurement of the TDC and, similar to the
MDACC-HNLRS, also uses tape measurements and classification
of HNC lymphedema characteristics. These approaches are clinically feasible, cost-effective, and not time-intensive. The linear
measurements are estimated by the authors to take approximately
5 minutes to measure by clinicians experienced with HNC survivors, making them not time intensive. However, the inclusion
of the TDC increases the time to complete the measurement and,
in total (linear and TDC measurement), we estimate these could
take up to 10 minutes. Ten minutes could take up one third of the
time to evaluate or treat a non-complex patient, even more time
may be required if the physical therapist needs to re-measure. At
20

this point though, TDC is not commonly used clinically and is not
likely to be found in the average clinic.
The techniques of ultrasound, 3D scanning, and TDC methods hold great promise for clinical translation but all need more
research investigating their psychometric properties of reliability
and validity, sensitivity to change, and references for comparison.
All 3 are used to measure external edema and, while none addresses the measurement of internal edema, they are noninvasive
and not dependent on a skill set possessed only by physicians.
Like MRI and CT-scanning methods, 3D laser scanning can precisely measure external lymphedema and does not require a medical referral. The disadvantage is that the entire volume of the head
and neck region is assumed to be included in the overall volume
measure. To illustrate, it assumes that the scanned area is a solid
with no “empty” spaces such as the oral cavity, sinuses, pharynx,
larynx, and upper esophagus. Of these 3 methods dependent on
the use of technology, 3D scanning is prohibitively expensive and
presents a steep learning curve for the physical therapist. In addition to the 3D laser scanner (of which there are several types to
choose), the clinic will also need to purchase 3D computer software to measure volume. The computer programs are complicated
and require intensive training. Other costs associated with the use
of the 3D scanner include software training, service agreements,
software updates, repair costs, and costs for personnel to take the
images and render them usable in 3D software.
In contrast, the TDC is a small hand-held device that provides
fast and readily available measurements. The TDC measures the
electrical properties of lymphatic fluid—not necessarily edema
like 3D scanning—but it is comparable to the MDACC-HNLRS
and ALOHA systems. Likewise, ultrasound holds promise and
further research is warranted. We caution that the 3D scanners,
real-time ultrasound, and TDC devices may be cost-prohibitive
for a clinic to purchase.
Measurement of head and neck lymphedema poses many
challenges to physical therapists. Methods that are clinically realistic are limited and few have had in-depth testing with patients
with HNC. Head and neck cancer is a rare tumor type and patients
tend to be very sick during active treatment, making it difficult
to recruit and retain large samples for research. The MDACCHNLRS and the ALOHA measurement systems are the best available and feasible measures for use in the physical therapy clinic.
Collected prospectively and across clinics, these measurement
systems may provide important data for future research and comparability across clinics.
While we focused on measurement of external edema for the
HNC survivor with cancer-related lymphedema, it is clear that
much more research needs to be conducted to address the complex cluster of issues typical of lymphedema. Future research
will address this through the review of PROs related to QOL and
lymphedema.
CONCLUSIONS
Measurement of lymphedema of the head and neck is in its
Rehabilitation Oncology
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infancy. Few methods exist to calculate volume and/or physiological properties that characterize lymphedema of the head and neck.
Volume assessment using tape measures and specific landmarks
are the most commonly used method currently, but other methods
such as 3D scanning, ultrasound, and TDC hold great promise.
However, because of the lack of good psychometric properties
or clinical utility, no outcome measures for objectively quantifying external edema for the HNC population can be recommended
at this time. The future development and application of these
devices to measure edema in HNC survivors with lymphedema
merits systematic and comparative research to evaluate measurement properties such as reliability, validity, sensitivity to change,

and normative values. Much research needs to be conducted to
develop and compare a variety of methods for edema of the head
and neck. We recommend that physical therapists fully weigh the
advantages and disadvantages of any measure of edema while
treating HNC survivors.
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Provide a structured summary including, as applicable: background; objectives; data sources; study
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results;
limitations; conclusions and implications of key findings; systematic review registration number.

15

INTRODUCTION
Rationale
Objectives

3

Describe the rationale for the review in the context of what is already known.

4

Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).

15-16
16

METHODS
Protocol and registration
Eligibility criteria
Information sources

5

Indicate if a review protocol exists, if and where it can be accessed (eg, Web address), and, if available, provide registration information including registration number.

16

6

Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years
considered, language, publication status) used as criteria for eligibility, giving rationale.

16

7

Describe all information sources (eg, databases with dates of coverage, contact with study authors to
identify additional studies) in the search and date last searched.

16

Search
8

Study selection

Present full electronic search strategy for at least one database, including any limits used, such that it
could be repeated.

Figure 1
Please also see the
Data & Methods
section on page 16

9

State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if
applicable, included in the meta-analysis).

16

10

Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and
any processes for obtaining and confirming data from investigators.

16

11

List and define all variables for which data were sought (eg, PICOS, funding sources) and any
assumptions and simplifications made.

16

Risk of bias in individual
studies

12

Describe methods used for assessing risk of bias of individual studies (including specification of
whether this was done at the study or outcome level), and how this information is to be used in any
data synthesis.

16

Summary measures

13

State the principal summary measures (eg, risk ratio, difference in means).

NA

14

Describe the methods of handling data and combining results of studies, if done, including measures
of consistency (eg, I2) for each meta-analysis.

NA

Data collection process
Data items

Synthesis of results
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ABSTRACT
Background: Outcomes from standardized exercise tests (SET)
are used by physical therapists (PTs) to define cardiorespiratory
fitness (CRF) and develop safe and effective prescriptions for
aerobic exercise training programs; however, the psychometric
properties and clinical utility of standard exercise testing has
not been evaluated in the breast cancer survivor population.
Objective: To evaluate the psychometric properties, safety, and
clinical utility of SET and provide informed recommendations for
their use in clinical practice involving female breast cancer survivors. Design: The study was a systematic review with a measurement focused design. Methods: A comprehensive search was
performed with a health sciences librarian to identify articles that
reported psychometric data on SET among women with breast
cancer. Criterion articles were evaluated using the Cancer EDGE
Task Force Outcome Measure Rating Form. Results: Sixty-eight
articles met initial inclusion criteria, but only 5 were found that
reported useable psychometric data. Maximal treadmill and cycle
ergometer tests involving expired gas analysis were valid and
accurate in this population, but are not safe or efficient for use in
a clinical setting. Submaximal tests (treadmill, cycle ergometer,
step, and walk/run tests) that use prediction equations to estimate
CRF had large errors for minimal detectable differences (3.3215.80 ml/kg/min) which approached or exceeded the minimal
clinically important difference (3.5 ml/kg/min). Furthermore,
these prediction equations have not been validated in this population. Discussion: Limited evidence was found describing the
psychometric properties of SETs used to determine CRF in breast
cancer survivors. Available studies suggest clinically efficient
SETs have moderate to poor concurrent validity with a moderate
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PhD, Oakland University, School of Health Sciences,
Physical Therapy Program, 3155 Human Health Building,
Rochester, MI 48309-4482, Ph: (248) 364-8684, Fax: (248)
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to high standard error; however, standardized exercise testing can
serve to screen for exercise safety and provide estimates of CRF.
Exercise prescriptions developed from the outcomes of SET will
require follow up for potential modifications. Appreciating SET
limitations enables proper client education and training adjustments needed for safety and exercise efficacy. Conclusions:
Further understanding of the psychometric properties of SET
used in the breast cancer survivor population is needed in order
to make these tests safe, accurate, and clinically useful.
Key Words: aerobic exercise testing, psychometrics, clinical
utility, cardiorespiratory fitness, submaximal exercise, maximal
exercise
INTRODUCTION
Aerobic exercise (AE) is recommended as a safe and effective method for reducing treatment related side effects and
promoting cardiorespiratory fitness (CRF) in women with breast
cancer.1,2 Available evidence suggests that AE may enhance
cancer treatment efficacy and induce changes in gene expression
and cancer biology, which might prevent an initial occurrence or
a reoccurrence of cancer.1-4 Based on this positive evidence for
health promotion and cancer prevention, it becomes the physical
therapist’s role to develop safe and effective exercise prescriptions predicated on using accurate and clinically appropriate clinical tests of CRF.1-3,5-8 Current consensus statements recommend
using standardized exercise tests (SET) according to established
professional guidelines to determine CRF.2,5-10 However, available consensus statements acknowledge that the psychometric
properties of established SETs were developed using non-cancer
populations; therefore, the accuracy and applicability of CRF
measures in breast cancer survivors is not known.1,2,9-11
Accurate cardiovascular screening and exercise testing is
particularly important for breast cancer survivors since cancer
treatments and adjuvant therapies cause varying amounts of
acute and/or long-term cardiovascular disorders.1,2,9,12-14 These
disorders include hypertension, endocardial fibrosis, arrhythRehabilitation Oncology
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mias, bradycardias, progressive declines in left ventricular function, and heart failure.13,14 Furthermore, a review of exercise
testing outcomes from cancer patients found markedly reduced
CRF levels compared to apparently healthy subjects that were
attributed to cancer treatments, aging, and sedentary lifestyles.3
This elevated cardiovascular risk signals the need for appropriate cardiovascular screening, and, when indicated, CRF testing
to insure that exercise prescriptions are safe and effective.2,9
Admittedly, there are screening tools such as surveys and walking tests (6 minute walk test) that are associated with physical
function and have proven to be clinically useful.5 However, these
assessments do not measure or readily predict CRF, an outcome
required for the development of effective exercise prescriptions
or for screening for disease. Therefore, these assessments will
not be evaluated in this paper.2,5
While a considerable body of evidence exists describing the
psychometric properties of SET measures of CRF in apparently
healthy individuals and individuals with cardiovascular disease,
the psychometric properties of SET used in assessing the CRF of
breast cancer survivors has not been previously evaluated.1,9,15-42
Therefore, the purpose of this study was to evaluate the psychometric properties, safety, and clinical utility of SETs in order to
make informed recommendations regarding their use in clinical
practice for the purpose of measuring CRF in female survivors
of breast cancer.
METHODS
A systematic review using a measurement focused design
was used to find and evaluate articles that contained data on the
psychometric properties of SETs used in female survivors of
breast cancer. The clinical utility and safety of these tests was
also examined. The literature search was initially performed by
graduate students in a Doctor of Physical Therapy program with
guidance from a University Health Sciences Librarian. Criterion
articles were written in English or had a published abstract
written in English. The search began online using CINAHL,
PEDro, Pubmed (Medline), Cochrane, Science Direct, Hooked on
Evidence, Web of Science, Scopus, and Sport Discus databases.
References listed in the selected criterion articles were also evalu-

ated for potential inclusion. Key search words included: breast
neoplasm, breast cancer, cancer, SET, aerobic capacity, aerobic
exercise, aerobic endurance, cardiorespiratory fitness, cardiovascular endurance, maximal oxygen consumption, VO2max,
psychometrics, reliability, validity, standard error of the measure
(SEM), minimal detectable difference (MDD), minimal clinically
important difference (MCID), SET, standardized SET, treadmill
test, cycle ergometer test, walk tests, run tests, and step tests.
The psychometric properties, safety, and clinical utility of
the SETs were reviewed using the Cancer EDGE (Evidence
Database to Guide Effectiveness) Task Force Outcome Measure
Rating Form. This evaluation tool uses a format adapted from
the Section on Research EDGE Form and recommended by
the American Physical Therapy Association EDGE task force.
Although this tool recommends limiting the search to articles
published in the previous 10 years, the SET psychometric studies
began in the 1930s, so no date limitation was applied to articles
in the search. The evaluators were two physical therapists with
advanced academic degrees in exercise physiology, research
design, and statistics. The evaluations ratings used were the
categories from the Breast Cancer EDGE tool seen in Table 1.
When evaluation ratings did not agree, the authors reviewed the
evidence to achieve consensus.
Criterion articles were from original studies that presented
the psychometrics, safety and clinical utility of SETs used in the
breast cancer population. Articles were also included if the data
provided could be used to calculate concurrent validity, test-retest
reliability, SEM, MDD, and MCID. Articles were removed that
did not include data from a SET, did not clearly explain the type
of SET performed, or that used functional assessments or reported
fitness derived from surveys or self-reports. Systematic reviews,
commentaries or recommendations, or practice guidelines were
not reviewed; however, reference lists from these sources were
examined for potential references.
RESULTS
Initially, 3837 articles were identified through key word
searches of online data bases. Following removal of duplicates
(n = 1803) and non-criterion articles through title and abstract

Table 1. Breast Cancer EDGE* Evaluation Categories
4

Highly Recommend

Highly Recommend; the outcome has excellent psychometric properties and clinical utility; the measure has been used in
research on individuals with or post breast cancer.

3

Recommend

Recommend; the outcome measure has good psychometric properties and good clinical utility; no published evidence that
the measure has been applied to research on individuals with or post breast cancer.

2A

Unable to Recommend
At this time

Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure;
the measure has been used in research on individuals with or post breast cancer.

2B

Unable to Recommend
At this time

Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure;
no published evidence that the measure has been applied to research on individuals with or post breast cancer.

1

Do not Recommend

Poor psychometrics &/or poor clinical utility (time, equipment, cost, etc.).

* Cancer EDGE (Evidence Database to Guide Effectiveness) Task Force Outcome Measure Rating Form; adapted from the Section on Research EDGE Form recommended by the APTA EDGE Task Force.
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reviews (n = 1984), and then adding 18 articles from reference
checks, 68 articles were selected for review (Figure 1). Of these
articles, 5 were identified that included psychometric data or data
that could be used to calculate psychometric values in the breast
cancer population. Two studies were also found that examined
the safety of exercise testing conducted in female breast cancer
survivors.
Evidence from sports medicine and science journals recommend that concurrent validity and test-retest reliability are
the psychometrics most appropriate for evaluating SETs.15,43,
44
Concurrent validity is the degree to which SET measures
agree with those obtained using gold standard measures.17,43,44
The statistical analyses used to determine concurrent validity
are Intraclass Correlation Coefficients [ICC (model 2, 1 or 2, k)]
and Coefficients of Variation (COV).15,44,45 The ICC provides a
measure of the agreement between two or more tests expressed
as values between 0 and 1.0.20,44 Higher values represent better
agreement; however, the values are difficult to interpret and there
is controversy regarding the level viewed as acceptable.15,43-45
Some older articles suggest that correlation coefficients of .75
or higher are excellent, while more current reviews indicate that
the ICC must be .90 or higher for a test to be useful in clinical
practice and research.15,43,45,46 Prior studies have also used the
Pearson Product Moment (r) to determine associations between
tests; however, this statistic is not the preferred method as it is
not able to account for systematic error and it overestimates associations when samples are small.15,43-45 Based on the evidence, a
rating of excellent in this review required a value of .90 or above.
Measures of concurrent validity for various SET appear in Table
3 and Table 4; when the ICC was not available, the Pearson
Product Moments was instead reported.

Figure 1. Flow of literature search process for psychometric
measures.
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The COV presents the typical error as the percent change
in the mean.15,45 The COV is a straightforward, dimensionless
measure that enables comparisons of scores from different types
of subjects (males vs females) as well as different tests (treadmill vs cycle ergometer). As such, the COV is easier to interpret
and may be more useful in clinical and research settings.15 The
lower the COV value, the higher the agreement with the gold
standard measure; however, some authors suggest that 5% or
higher represents poor reliability and this standard was used in
the current evaluation.20 The COV values derived from sport and
performance tests appear in Table 3 and Table 4. When the COV
was not available, the percent difference between the tests was
reported.
Test-retest reliability provides a measure of the precision or
reproducibility of SET measures taken over time and it can be
used to assess the exercise device, the test protocol, the subject,
as well as the raters.15 The recommended statistics again are the
ICC (model 3, 1) and the COV as described previously.46
Standard errors of a measure are clinically useful for determining both concurrent validity and test-retest reliability.44 Like
the COV, the SEM is a calculation of the typical error and it is
robust to small samples.15,44 The SEM is clinically useful as it
is reported in the same units as the test data.15,44 For example,
an SEM of 0.05 ml/kg/min for an SET for an MCID of 3.5 ml/
kg/min would be considered excellent agreement. However, an
SEM for an SET that approaches or exceeds the MCID would
be invalid and unreliable for measuring CRF and subsequently
developing safe and effective exercise prescription intensities.
The SEM is also used to calculate the MDD which allows clinicians to determine whether changes in a patient’s score were
real or simply within the error of the measure; therefore, lower
MDD values were associated with higher levels of accuracy.43
The values for test-retest reliability appear in Table 3 and Table
4. When the SEM was not reported, the standard error of the
estimate (SEE) was provided.
Maximal Exercise Tests
Maximal SETs complete with gas analysis can be performed
using a treadmill or a cycle ergometer.2 Both methods require the
subject to perform a maximal physical effort and analyze expired
gases for O2 and CO2 content which is then used to calculate
maximal oxygen consumption or VO2max.2 The criteria defining
a maximal CRF SET includes plateauing of the heart rate and/
or oxygen consumption despite increases in the workload and a
respiratory exchange ratio (CO2 released/O2 consumed) of 1.15 or
greater.17-19 However, not all individuals are able to reach maximal cardiorespiratory levels due to musculoskeletal, neuromuscular or other physical limitations.2,6-8 It is also not safe for many
individuals to perform maximal exercise, particularly if they have
known or suspected cardiovascular conditions.2,6-8
Maximal oxygen consumption is measured in milliliters
per kilogram body weight per minute (ml/kg/min) which is a
standardized value that allows for comparisons between individuals or across time for a single individual which can be used
to asses changes in CRF.17-19 The MCID derived from studies in
Rehabilitation Oncology
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Table 2. Standardized Exercise Test Outcomes: EDGE Task Force Rating & Clinical Utility
Standardized
Exercise Test

Task Force
Rating

Psychometrics

Clinical Utility and Safety

Maximal Tests with Oxygen Analysis

Treadmill

Cycle
Ergometer

1
Do not
Recommend

1
Do not
Recommend

·
·
·

·
·
·

Used in 14 breast cancer research intervention studies
Psychometrics for valid CRF measures found in one breast
cancer study
Excellent validity and reliability from non-breast cancer
studies

·
·
·
·
·
·

Very expensive
Time intensive (45-60 min)
Specialized training
Requires 2 clinicians to perform
Often requires physician onsite
Contraindicated in national practice standards due to
safety risks of performing maximal exercise

Used in 15 breast cancer intervention studies
Psychometrics found adequate for test-retest reliability in
one breast cancer study
Psychometrics from non-breast cancer studies were poor to
excellent for concurrent validity and moderate to poor for
clinical relevance as MDD may exceed MDIC

·
·
·
·
·
·

Very expensive
Time intensive (45-60 min)
Specialized training
Requires 2 clinicians to perform
Often requires physician onsite
Contraindicated in national practice standards due to
safety risks of performing maximal exercise

Submaximal Tests with Prediction Equations
·
·

Treadmill

2A
Unable to
Recommend
At this time

·
·

·
·
Cycle
Ergometer

2A
Unable to
Recommend
At this time

·
·

Used in 7 breast cancer research studies
Prediction equations for heart rate maximum to determine
submaximal test endpoints and CRF found invalid in 2
breast cancer studies
Psychometrics not assessed in breast cancer research studies
Psychometrics from non-breast cancer studies are fair to
good for concurrent validity but standard errors were high
and the MDD exceeded the MDIC contributing to poor
reliability.

·
·
·

Used in 5 breast cancer research studies
Psychometrics poor for sensitivity and concurrent validity with VO2max cycle ergometer tests in 2 breast cancer
studies
Psychometrics adequate for test-retest reliability in one
breast cancer study
Prediction equations for heart rate maximum to determine
submaximal test endpoints and CRF were invalid in 2
breast cancer studies

·
·
·

·
·

·
·

Low cost and easy to administer
Less time to administer (20-30 minutes)
Requires 2 clinicians: one performs test and other onsite
for safety concerns
Requires following standardized protocol and accurate
heart rate measures
Safe to administer with proper pre-screening. Monitoring
and patient instructions

Low cost, portable, and easy to administer
Less time to administer (20-30 minutes)
Requires 2 clinicians: one performs test and other onsite
for safety concerns
Requires following standardized protocol and accurate
heart rate measures
Safe to administer with proper pre-screening. Monitoring
and patient instructions

Field Tests
12-Min Run

1
Do Not
Recommend

·
·
·

Not used in breast cancer research
MDD exceeds MCID
Validity of CRF prediction equations not assessed in breast
cancer research

·
·
·
·

Easy to administer
Low cost
Can assess multiple subjects at same time
Contraindicated due to safety as vital signs not monitored during test and there is potential to perform a
maximal test

12-Min Walk

2A
Unable to
Recommend
At this time

·
·
·

Used in 5 breast cancer research studies
MDD and SEM not defined
Reliability and Validity not determined for breast cancer
survivors
Validity of CRF prediction equations not assessed in breast
cancer research

·
·
·
·

Easy to administer
Low cost
Can assess multiple subjects at same time
Contraindicated due to safety as subjects vital signs are
not monitored during testing and there is potential to
perform a maximal test

·
1-Mile Walk

2A
Unable to
Recommend
At this time

·
·
·

Used in breast cancer research
·
MDD and SEM not defined
·
Validity of CRF prediction equations not assessed in breast ·
cancer research

Easy to administer
Can assess multiple subjects at same time
Requires vital signs monitoring for safety as potential to
perform a maximal test

Step Test
(Canadian
Aerobic
Fitness Test
protocol)

2A
Unable to
Recommend
At this time

·
·

Used in one breast cancer research study
Psychometrics for not assessed in breast cancer research
studies
Validity of CRF prediction equations not assessed in breast
cancer research
Standard errors were high and the MDD exceeded the
MDIC contributing to poor reliability.

Easy to administer
Low cost
Can assess multiple subjects at same time
Requires fixed step height and cadence
Safety issues related to balance and falls, and vital signs
not monitored during test leading to potential to perform
a maximal test
Requires high MET levels not appropriate for sedentary
or low fitness individuals

·
·

·
·
·
·
·

·

Abbreviations: CRF, cardiorespiratory fitness; MDD, minimal detectable difference; MCID, minimal clinically important difference; SEM, standard of measurement

Rehabilitation Oncology
Vol. 33, No. 2, 2015

27

Table 3. Concurrent Validity
Exercise Test

Concurrent
Validitya

Population Assessed

COV or Percent Difference
between Meansb

Standard Error
of the Measurec
ml/kg/min

Minimal Detectable
Differenced
ml/kg/min

Maximal Tests with Oxygen Analysis
Treadmill
Test

Cycle
Ergometer

Healthy Males & Females, Athletes17-19

ICC = .97

<1.5-2.0%
(with Douglas Bag)

± 0.05-0.06

± 0.15 - 0.17

Women with Breast Cancer

Not found

Not found

Not found

Not found

Healthy Males & Females, Athletes16-19

R2 = .60-96

COV = 1.5 (1.1-2.0)

- 0.7 to 1.3
SEE = - 4.5

1.9-3.6

Women with Breast Cancer55
(Reported as raw difference and percent)

Not found

Not found

Not found

- 16.7%B
(-4.8 ml/kg/min)

Submaximal Tests used with Prediction Equations
Treadmill
Test

Cycle
Ergometer

12 Minute
Run

12 Minute
Walk

1 Mile
Walk

R2 =.76-.88

Not found

± 3.4 – 5.3

Women with Breast Cancer

n/a

n/a

n/a

Healthy Males & Females, Athletes,
Individuals with Cancer16-19, 27, 34, 71

R2 =.61-.96
R2 = .50-.62 10

9.4 - 16.6%
-9.0%71
(Compared to V̊ O2max
cycle ergometer)

SEE = 3.12-4.23

Women with Breast Cancer

Not found

Not found

Not found

Not found

Healthy Males & Females, Athletes17-19, 27

R2 = .02-.85
(not a typo)

n/a

n/a

n/a

Women with Breast Cancer

Not found

Not found

Not found

Not found

Individuals with Heart and Lung Disease 27, 37

R2 = .24-.27

n/a

n/a

n/a

Women with Breast Cancer

Not found

Not found

Not found

Not found

Healthy Males & Females16, 34, 38-40

ICC=.96-.97
R2 = .62-86

Not found

SEE = 5.68
SEE 0.325 L/min

Not found

Not found

Not found

Not found

Not found

Healthy Males & Females, Athletes17-19, 33-35

R2 = .62-.85

-3.8%

SEM = 4.08
SEE = 2.9–4.1

11.3

Women with Breast Cancer

Not found

Not found

Not found

Not found

Women with Breast Cancer
Step
Test

9.4-14.7

Healthy Males & Females, Athletes17-19,

n/a
11.6-15.8

The Pearson Product Moment (r) was reported when Intraclass Correlation Coefficients (ICC) were not found.
Percent difference was reported when the Coefficient of Variation was not found.
c
Standard Error of the Estimate (SEE) was reported when Standard Error of the Measure (SEM) was not found.
d
Minimal Detectable Difference (MDD) at 95% Confidence Level.
a

b

apparently healthy people is one metabolic equivalent (MET),
which is equal to 3.5 ml/kg/min of oxygen.2,42,43 The 3.5 ml/kg/
min definition for the MET is lower in women than in men and
it also gradually decreases with aging; however, the validity of
the MCID measure has not been determined among breast cancer
survivors.2,42,43
VO2max Treadmill Tests
Extensive study and scientific evidence from other populations supports the VO2max treadmill SETs as the gold standard for accurate measurement of CRF.2,9,15,17-21 These tests
are performed on a motor-driven treadmill with expired gases
28

analyzed for O2 and CO2 content. Administration time is about
45 to 60 minutes including time for set-up, preparation, warm-up,
testing, and cool-down.2,9,15 There are a number of standardized
protocols available for use in different populations, all involving
a step-wise, progressive increase in exercise intensity until the
criteria demonstrating maximal exertion the maximal criteria has
been achieved.2,17-19
Twenty-three articles were initially found that used VO2max
treadmill testing to determine the CRF of breast cancer survivors; however, several of these papers were secondary analysis
of original data sets resulting in only 14 original sets of exercise
test data.47-69 Unfortunately, the majority of the studies did not
Rehabilitation Oncology
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Table 4. Test-retest Reliability: Standardized Exercise Tests
Exercise Test

Test-Retest
Correlationa

Population

Percent
Differenceb

Standard Error of
the Measurec
ml/kg/min

Minimal Detectable
Difference

Maximal Tests with Oxygen Analysis
Treadmill
Test

Cycle
Ergometer

Healthy Males & Females16-20,25,26, 107

ICC = .95

2.0-5.0%
COV = 0.9D

2.58107

Not found

Women with Breast Cancer

Not found

Not found

Not found

Not found

Healthy Males & Females, Athletes17-20

R2 = .74-94

COV = 0.9d

Women with Breast Cancer

Not found

Not found

- 8.1%

n/a

Not found

Not found

Submaximal Tests with Prediction Equations
Treadmill
Test

Cycle
Ergometer

Healthy Males & Females, Athletes17-19, 34

R2 = .85

Not found

Not found

Not found

Women with Breast Cancer

Not found

Not found

Not found

Not found

Healthy Males & Females, Athletes, individuals
with Cancer17-19, 27, 71.96

ICC = .95-.9917-19, 97
ICC = .87371

Not found

1.517-19, 27
-.02 ± 3.2996, e

3.32

Women with Breast Cancer

Not found

Not found

Not found

Not found

Not found

Not found

Not found

Not found

Not found

1.6

4.54

Step
Test

Women with Breast Cancer

Not found

Not found

Healthy Males & Females27

F = .96

Not found

Women with Breast Cancer

Not found

Not found

Not found

Not found

Individuals with Heart and Lung Disease 37

ICC=.96-.99

COV= 4.2-8.6

Not found

Not Found

Women with Breast Cancer

Not found

Not found

Not found

Not found

Healthy Males & Females40

ICC = .97

Not found

Not found

Not found

Women with Breast Cancer

Not found

Not found

Not found

Not found

12 Minute
Run

12 Minute
Walk

R2 = .62

Healthy Males & Females36

1 Mile
Walk

When Intraclass Correlation Coefficients (ICC) were not found; R2 was reported.
Percent difference was reported when the Coefficient of Variation was not found.
c
Standard Error of the Estimate (SEE) was reported when Standard Error of the Measure (SEM) was not found.
d
Calculated for peak VO2 measures, not always with oxygen analysis.
e
Limits of Agreement.
a

b

explain whether the subjects’ performance met the criteria for
maximal exertion and many did not report oxygen consumption
in ml/kg/min. These reporting problems have been cited in prior
reviews as they prevent scientific interpretation of the results
as well as calculation of psychometric measures.9,10 Only one
article provided data sufficient to demonstrate that the subjects
met the VO2max criteria, which suggests that this mode of SET
is valid in this population.57 Although the psychometric properties for VO2max treadmill tests undertaken by healthy populations and individuals with heart disease are available, no studies
were found that presented correlation coefficients for test-retest
reliability, COV, SEM, MDD, or MCID specifically for VO2max
treadmill tests performed by breast cancer survivors.
VO2max treadmill tests are the recommended method
for evaluating CRF because of the accuracy of its measureRehabilitation Oncology
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ments.2,9,15,17-21 Despite its status as the gold standard measure,
VO2max treadmill testing is not recommended in national standards written for exercise testing in the clinic.2,5-8,19 These tests
are time-consuming, expensive to perform, and require specialized and costly equipment.2,5-8 These tests also require advanced
training for the test administrators and the presence of at least two
clinic staff members for safety during testing.2,5-8 Depending on
the subject’s physical status, a physician may be required to be
on-site during testing.2,5-8 Most importantly, national guidelines
for clinical practice do not deem maximal exercise testing as
being safe for many individuals when performed in the clinical setting.2,5-8 Therefore, based on clinical efficiency and safety
concerns, the EDGE rating for maximal treadmill tests with
oxygen analysis was: “1 - Do not Recommend.”
29

VO2max Cycle Ergometer Tests
Maximal oxygen consumption testing can also be performed
using a bicycle ergometer. As with maximal treadmill exercise
testing, VO2max cycle ergometer tests require subjects to perform
a maximal physical effort to criterion endpoints and measures
CRF (VO2/ml/kg).2 A mechanically-braked cycle ergometer
provides standardized pedal resistance that can be used in
various single and multi-stage protocols.2 Since the subject is
seated, the test can be used for individuals who are unable or are
unsafe to walk on a treadmill.2 The test takes approximately 45
to 60 minutes to administer.2,34 In studies on apparently healthy
subjects, test-retest reliability can be good if standardized testing
guidelines are followed.2,15,16 However, cycle ergometer measures
are approximately 10% lower than gold standard measures,
which reduces the test’s concurrent validity.2,15,20,28,46
Fifteen studies were found that used VO2max cycle
ergometer tests to determine the CRF levels of female breast
cancer survivors.55,70-83 Only one of these studies presented the
psychometric properties of maximal cycle ergometer SETs
among breast cancer survivors. Dolan et al found poor concurrent
validity between VO2max cycle ergometer measures and VO2max
treadmill measures among 12 breast cancer survivors.55 The cycle
ergometer measures were 4.8 ml/kg/min lower than measures
obtained from the treadmill test and this difference exceeded the
MCID for CRF measures.55
Studies from other populations found acceptable test-retest
reliability measures; however, studies from women with breast
cancer and other populations found the concurrent validity with
gold standard measures was poor.16.34,55 In addition, similar to
VO2max treadmill tests, VO2max cycle ergometer tests are not
recommended in national standards for clinical exercise testing
due to the poor clinical efficiency and safety concerns for
patients.2,5-8,19 Therefore, the EDGE rating for VO2max cycle
ergometer tests was: “1 - Do not Recommend.”
Submaximal Exercise Tests
Because of the safety concerns associated with maximal
exercise testing, exercise testing protocols requiring submaximal
exertional efforts are available and widely used clinically. These
tests do not involve analysis of expired gases and are stopped
at a predetermined exertional level. Resulting physiologic data
(heart rate, time) as well as anthropometric data are entered into
derived equations or prediction equations which generate estimates of VO2max.2,34 Therefore, subject preparation, precise heart
rate measurement, and valid prediction equations are required
for estimates of CRF to be accurate.2,28,34,39,41 Since subjects do
not perform a maximal physical effort, submaximal tests offer a
safer alternative to maximal testing as long as proper screening,
monitoring, and patient instructions are provided.2,5-8,34 Also, the
costs associated with a metabolic cart and specialty training are
not required since oxygen analysis is not performed.
Submaximal Treadmill Tests
Submaximal treadmill testing protocols often use the same
protocols as VO2max treadmill tests.2,28,34 Testing takes approximately 20 to 30 minutes and typically the test ends when individ30

uals reach 70% of their heart rate reserve, 85% of their predicted
maximal heart rate, or they develop adverse signs and symptoms.2,28,34 Eight published articles were found that appeared to
consist of 7 original data sets derived from female breast cancer
survivors who had undergone submaximal treadmill testing.84-92
The tests primarily tracked changes in CRF following subject
participation in exercise training interventions. Studies on nonbreast cancer subjects found the SEM could exceed the MCID
for concurrent validity and test-retest reliability if standardized
testing protocols were not followed.2,34,41 Two studies examining
survivors of breast cancer found that current equations used to
estimate maximum heart rate overestimated maximal heart rate
by approximately 10 beats per minute.57,58 One of these studies
also suggested that reported ratings of perceived exertion were
significantly lower than predicted values for specified exercise intensities.57 A study by Evans et al examined differences
in heart rate, ratings of perceived exertion, and blood lactate
concentrations between women with breast cancer and apparently healthy women at various exertional intensities.92 Results
demonstrated that these physiologic measures were similar
between these groups at low to moderate exertional levels, but at
70% of VO2max blood lactate levels were significantly different,
suggesting differences existed in the physiological responses of
survivors of breast cancer to moderate to high intensity exercise.
In turn, these findings suggest that a better understanding of these
differences is needed in order to write safe, appropriate, and
effective exercise prescriptions.
In summary, submaximal treadmill tests have been used
in breast cancer studies to provide an estimate of CRF and are
relatively easy to administer and safe with proper screening
and monitoring.1,2,11,83 These tests offer improved clinical utility
relative to time spent in testing, equipment costs, and specialty
training. However, psychometric measures may be unacceptable
and the equations used to predict CRF require further validation.
Therefore, the EDGE rating for submaximal treadmill tests was:
“2A - Unable to Recommend at this time.”
Submaximal Cycle Ergometer Tests
Submaximal cycle ergometer tests are also available and
utilize prediction equations to estimate CRF and to determine test
endpoints.2,16,28,34 Therefore, the costs of a gas analysis equipment
and specialty training are eliminated. Because these are submaximal tests, subjects are not required to perform a maximal effort;
therefore, with proper screening, the tests are safer to perform.2,34
The test is clinically efficient and takes approximately 20 to 30
minutes to administer.2,16,28,34
Five studies were found that used submaximal cycle ergometer tests in breast cancer research and two studies measured
psychometric properties.71,78,93-95 Debacker et al compared
measures from a submaximal cycle ergometer test to a maximal
short exercise capacity test (steep ramp test) and a VO2max cycle
ergometer test to detect changes in CRF after an 18-week training program among male and female cancer survivors.71 The
submaximal cycle ergometer tests proved invalid for detecting
changes in CRF following exercise training compared with the
two maximal tests (r = .71 to .79). The study did calculate testRehabilitation Oncology
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retest reliability for the submaximal cycle ergometer test in this
population as good as ICC = .873 (CI95 =.72 to .95). A subsequent
study by May et al also examined the sensitivity of submaximal
cycle ergometer tests to detect changes in CRF following training in subjects with cancer.78 The study found a modest, but poor
correlation [r = -.51 (p = .006)] for the sensitivity of submaximal cycle ergometer measures compared with VO2max cycle
measures. The subjects in both the Debacker et al and the May et
al studies had a variety of cancer diagnoses and data was reported
in aggregate, so results specific for female breast cancer survivors
were not available.
One additional study was found that examined test-retest reliability for the submaximal cycle ergometer test with oxygen analysis in subjects with lymphohematopoietic cancers.96 Although
this study did not include women with breast cancer, it did
provide psychometrics for test-retest reliability for a submaximal
cycle ergometer test of ICC = .96 among individuals with cancer
which was excellent. Limits of agreement (LOA) and random
error measures were also provided as LOA = -.02 ± 3.29 which
can exceed the MCID for CRF measures.
Submaximal cycle ergometer tests have been used in breast
cancer research and they appear to offer improved safety with
proper screening. The tests also have good clinical utility relative to equipment cost and administration time.74,83 There is
also some psychometric evidence collected from women with
breast cancer.71, 78 Currently available evidence suggests testretest reliability for submaximal cycle ergometers is moderate to
good; however, standard errors continue to be large which may
contribute to inappropriate categorization of CRF and subsequent
errors in the exercise prescription intensities.71,78 Both studies also
suggest that submaximal cycle ergometer tests lack sensitivity to
identify changes in CRF following training.71,78 Finally, similar
to submaximal treadmill tests, ratings of perceived exertion and
prediction equations for test endpoints and CRF have not been
validated in the breast cancer population. The EDGE rating
for the submaximal cycle ergometer test was: “2A - Unable to
Recommend at this Time.”
Field Tests
Field tests also use derived prediction equations to estimate
CRF using distance, time, or heart rate responses during walking
or running tests.2,34 Common field tests include the 12 minute
walk (12-MWT) or run test, the 1.5 mile walk or run test, and the
1 mile walk test (1-MWT).2,34,38-40 Field tests are easy to administer, require little equipment, and often can be used to assess
multiple individuals simultaneously.2,34 The prediction equations
that estimate CRF from field test outcomes may require factors
such as age, gender, weight, and training status to improve the
estimate’s accuracy; however, the prediction equations must be
validated within each specific population.2,34,38-40 Field tests suffer
from the fact that vital signs are not monitored during testing
and individuals with low fitness levels or cardiovascular risk
may perform a maximal physical effort and compromise their
safety.2,34
Rehabilitation Oncology
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Twelve Minute Walk/Run Tests
The 12 minute walk and run tests use prediction equations
based on distance covered in 12 minutes to estimate CRF.2,34
The objective of 12 min walk and run tests is to cover as much
distance as possible within the allotted time. Cooper’s 12 minute
run test was the original assessment tool of this type and it was
developed using young athletic males.2,34 The 12-MWT is a
modification of Cooper’s run test; however, the walk test may be
more appropriate for individuals in the rehabilitation setting.2, 34
Both tests require a stop-watch or clock and a track with marked
distances. The test-retest reliability for the 12 minute run test
was reported as r =.90; however, concurrent validity is not clear
as values range from r = .13 to .90.2,27,34 Since vital signs are not
monitored during either test, there are safety concerns for individuals with low fitness or cardiovascular risk factors.2,34 There were
no articles found that validated the CRF prediction equations in
breast cancer survivors for either of these tests.
No articles were found that used or validated the 12 minute
run test in breast cancer survivors. The test is also not recommended for individuals with low fitness, cardiovascular risks,
or in rehabilitation due to safety concerns. Therefore the EDGE
rating for the 12 minute run test was: “1 – Do not recommend.”
Five articles were found that used the 12-MWT among breast
cancer survivors.97-101 The studies all referenced the concurrent
validity and reliability given for the Cooper 12 minute run test,
but no articles were found that provided psychometrics for the
12-MWT administered specifically to breast cancer survivors.
Since there were no psychometric measures or validated prediction equations for the 12-MWT for use with breast cancer survivors and there are safety concerns related to lack of vital signs
measurement during testing, the EDGE rating for the 12-MWT
was: “2A - Unable to Recommend at this Time.”
Distance Walk or Run Tests
The 1-MWT, also known as the Rockport Test, predicts CRF
fitness categories based on the heart rate obtained at or near the
end of the test. This test has been used and reported with walking
and running and has variations in the distances covered including:
1.0, 1.5, and 2.0 miles. This test appears to have good concurrent
validity (ICC = .96-.97) and test-retest agreement values (ICC
= .97) from other populations, although the SEM is not known.
The prediction equations derived from this test have not been
validated among breast cancer survivors. The test may also have
issues with safety since since again vital signs are not monitored
during testing.
Two studies were found that used a 1-MWT in breast cancer
research, although it appeared that the same data set was used for
the two different analyses.80,104 The test appears to be clinically
efficient and may be safe for the breast cancer survivors as long
as subjects are appropriately screened and vital signs are monitored during testing for safety.1,9,34 The test appears to have good
concurrent validity and test-retest reliability in other populations;
however, the prediction equations have not been validated for
use with breast cancer survivors. The 1-MWT may become a
clinically useful assessment; however, at the present time, the
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evaluators did not feel there was adequate evidence available to
recommend this test. Therefore, the EDGE rating for the 1-MWT
was “2A - Unable to Recommend at this Time.”
Step Tests
Step tests estimate CRF through equations that use the heart
rate response to stepping up and down stairs of a fixed height at
a fixed stepping rate.2,34 The test requires a criterion height step,
a metronome or audio cadence signal, and a stopwatch. The text
takes only a few minutes to perform and several subjects can be
tested at the same time. The test has good clinical utility since it
is low cost, requires minimal equipment, and is time-efficient.
Based on data from other populations, the test has moderate to
weak agreement with gold standard measures and the test-retest
reliability exceeds the MCID for low accuracy. The test also
requires energy expenditures of 7-9 METs, rendering it unsafe
or not possible for individuals with low fitness or cardiovascular disease to perform.2,34,103 The requirement for stepping
up and down from a specific height poses performance and
safety concerns for individuals with musculoskeletal, balance, or
sensory deficits (peripheral neuropathies) in the lower extremities.
One study was found that used a step test [Canadian Aerobic
Fitness Test (CAFT)] to assess CRF of women with breast
cancer.102 However, no studies were found which presented the
psychometric properties of step tests or the CAFT in the breast
cancer survivor population. The test is safe and clinically efficient
as long as individuals have a high fitness level, but issues with
accuracy and safety are a concern in the clinical setting. The
EDGE rating for the step test was: “2A - Unable to Recommend
at this Time.”
Exercise Testing and Training Safety
Two articles were found that examined the safety of maximal
cycle ergometer tests for women with breast cancer. Hornsby et al
found 12 non-significant ECG changes and 3 non-life threatening
events during 30 VO2max cycle ergometer tests performed by 10
women in treatment for breast cancer.74 Jones et al examined the
safety of VO2max cycle ergometer test among 85 individuals with
advanced cancers, 39 of whom had metastatic breast cancer.83
One female subject experienced a significant ECG change
(ST segment depression) and another experienced an exerciseinduced, asymptomatic right bundle branch block that normalized
at test termination. Both studies concluded that exercise testing
is relatively safe and effective for use in research among female
breast cancer survivors as long as proper screening, and vital
signs and ECG monitoring are performed. A few additional articles and reviews provided summary information based on the use
of exercise testing performed in research on breast cancer survivors that supported the safety of exercise testing and training as
long as standardized screening and monitoring is performed.1,70,78
DISCUSSION
The purpose of this study was to evaluate the psychometric
properties, safety, and clinical utility of tests used to assess or
32

estimate CRF for their use in clinical practice among women
with breast cancer. A systematic literature search yielded only
5 studies that assessed psychometric values for CRF measures
among women with breast cancer and two studies that assessed
safety.55-58,71,74,78,83
Three studies were found that reported the psychometric
measures derived from maximal tests and involving analysis
of expired gases. One study provided evidence that women
undergoing treatment for breast cancer could meet the criteria
for performing valid VO2max treadmill tests.57 This study and a
follow up study also found that currently used heart rate prediction equations significantly overestimate maximal heart rates for
women with breast cancer.57,5 In the event that maximal heart
rates are being overestimated with current equations, exercise
test endpoints and exercise prescriptions would be calculated
at higher than desirable intensities and pose safety and motivation concerns. A third study estimated the concurrent validity of
VO2max cycle ergometer tests and found CRF measures were
4.8 ml/kg/min lower, which exceeded the MCID of 3.5 ml/kg/
min. This suggests that individuals would be incorrectly placed in
lower CRF fitness categories and subsequently receive less effective exercise prescriptions, particularly if they were not exercising on a cycle ergometer.
Two studies were found that examined submaximal cycle
ergometer psychometric measures.71,78 Both studies found that
submaximal cycle ergometer measures were not sensitive to
detect changes in CRF following an exercise training intervention.71,78 Additionally, one of the studies did find that submaximal
cycle ergometer test-retest reliability (ICC = .873) was acceptable, although lower than values reported for apparently healthy
subjects (ICC = .95-.99).
This evaluation found very few studies on the psychometric
properties of CRF measures among women with breast cancer.
Furthermore, the psychometrics determined from other populations for tests with good clinical utility were not sufficiently valid
or reliable.2,16,34,38,40 Therefore, the highest ratings given in this
evaluation were: “2A - Unable to recommend at this time.” This
rating was given to submaximal treadmill and cycle ergometer
tests, step tests, the 12-MWT, and the 1-MWT. While the step
test may not be appropriate for all individuals, the decision to use
this test should be made by the clinician based on the individual’s
evaluation results. Three of the CRF measures received a rating
of: “1 – Do not recommend.” The CRF measures that received
this rating were the VO2max cycle ergometer and treadmill tests,
due to poor clinical utility and safety concerns based on national
guidelines.2,5-8 The 12 minute run test also received a rating of
“1 – Do not recommend,” since it had not been used in research
studies involving breast cancer survivors, the psychometrics were
not adequately determined, and due to safety concerns related to
the potential to perform a maximal test.2,27,34
Despite the current ratings presented in this evaluation,
physical therapist practice guidelines stipulate that some form of
screening or testing be performed prior to developing activity or
exercise prescriptions.5 Recommendations from other studies and
reviews suggest that current guidelines developed for apparently
Rehabilitation Oncology
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healthy subjects and individuals with cardiovascular and pulmonary conditions be used to guide exercise screening and testing
among individuals with cancer; however, the articles also recommend further research to support the validity, efficacy, and safety
of CRF testing for women with breast cancer.1,9,11,74,83
In terms of clinical practice, following professional guidelines for screening and testing will promote as much as currently
possible, valid, reliable and safe results.9 However, in the event
that exercise screening or testing protocols require modifications
to accommodate the patient’s needs or preferences, these adaptations should be noted in the physical therapy report to enable
accurate test replication and interpretation at a subsequent time.5
To promote accuracy and safety, clinicians need to appreciate
screening and testing risks and be aware of the individual’s health
status and possible cancer treatment co-morbidities. Some of
these conditions include: pain, nausea, dehydration, lymphedema
or shoulder pathology, breathing or movement difficulties related
to the surgery, reconstruction methods that may compromise corestability and place the individual at risk for back pain, cognitive
deficits (chemo-brain) or depression that may affect adherence to
exercise or judgment, a prior sedentary lifestyle, cardiovascular
toxicity from cancer medications, chest wall or pulmonary fibrosis from radiation treatments, metastasis to the bone which may
result in fractures or nerve compression, and secondary cancers
such as leukemia following treatments.13,14,105,106 Furthermore,
since breast cancer treatments combined with aging increase a
woman’s risk for cardiovascular disease, it is recommended that
CRF measures include vital signs monitoring to improve safety
or uncover abnormal responses to exercise.2,5,14
Finally, since submaximal exercise tests can have large SEM
and MDD that exceed the MCID, clinicians may wish to recognize that measures of CRF in female breast cancer survivors may
provide outcomes that over- or underestimate their CRF. Under
estimating CRF would lead to an ineffective activity prescription while overestimating CRF could lead to excessive fatigue,
discouragement, and disincentive to exercise. Furthermore, overestimating the exercise intensity could lead to excessive cardiovascular demands and promote arrhythmia, dyspnea, or even
death.2 Recognizing the limitations of CRF measures, clinicians
can promote safe and effective exercise training through patient
education on normal and abnormal exercise responses, information on when to contact the physical therapist regarding modifications to the exercise prescription, or when to contact a physician
or seek emergent care.
Limitations
The search process was limited to articles written or translated into the English language; therefore, the search process has
not been exhaustive. A second limitation was the small number of
articles found on the validity and reliability of CRF tests in female
breast cancer survivors. This lack of evidence prevented substantive and comprehensive evaluations and judgments. Confidence
in the findings was also limited by the quality of the reported data
which has been addressed in detail in prior reviews.9,10 Improved
reporting will allow for successful future evaluation studies and
clinical determinations.
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Future Study Recommendations
Recommendations for research on the psychometric properties of SETs used to assess the CRF in women with breast
cancer would include the following. First, additional studies are
required that determine concurrent validity, test-retest reliability,
and sensitivity to changes in CRF measures following an intervention. Second, cardiorespiratory fitness must be reported as
oxygen consumption in milliliters per kilogram per minute since
this measure can be compared over time for a single individual, as
well as across subjects. Third, SET endpoints need to be clearly
reported so that readers will know that the study subjects met
the required test criteria for accurate outcomes. Third, the proper
statistical analyses need to be used in order to have confidence
in the findings. The ICC or the COV are the recommended for
concurrent validity and test-retest reliability; however, the SEM
and MDD are also necessary to assess clinical relevance.15,44,46
Fourth, studies on concurrent validity require that comparisons
be made against gold standard measures as comparisons between
two non-criterion tests compounds errors. Fifth, to establish
reasonable precision for test-retest reliability, the recommendation is to have 50 subjects perform 3 trials each approximately
2.5 days apart.15,20 Finally, prediction equations that estimate
CRF, maximal heart rates, and perceived exertion ratings require
validation within this population.57,58 Ideally, evidence for the
psychometric properties of SETs would be useful across all stages
of breast cancer, all types of treatments, and through all survivorship periods.
CONCLUSION
This study evaluated the psychometric properties, safety,
and clinical utility of SETs used to determine or estimate CRF in
breast cancer survivors and provided informed recommendations
for their use in clinical practice among women with breast cancer.
However, the evaluation found limited evidence on the psychometric properties of CRF tests for this population. Suggestions
were made for adapting the current evidence for testing into clinical practice as well as for designing future research on this topic
among women with breast cancer.
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ABSTRACT
Background: Strength deficits are a common morbidity following treatment for prostate cancer. Accurate assessment of strength
and muscular endurance following prostate cancer treatments is
essential to identify deficits and plan rehabilitation. Purpose: To
identify strength and muscular endurance outcome measures that
possess strong psychometric properties and are clinically useful
for examination of men treated for prostate cancer. Methods:
Multiple electronic databases were searched for articles published
after 1995. Studies of tools used to assess strength and muscular
endurance were included if they reported psychometric properties, were clinically feasible methods, performed on adults, and
published in the English language. Each outcome measure was
independently reviewed and rated by two reviewers. A single
Cancer EDGE Task Force Outcome Measure Rating Form was
completed for each category of strength or endurance assessment,
and a recommendation was made using the 4-point Cancer EDGE
Task Force Rating Scale. Results: Of the original 683 articles
found, 30 were included in this review. Hand-grip strength and
hand-held dynamometry were rated 3, recommended for clinical
use. One repetition maximum was rated 2A, unable to recommend at this time but the measure has been used in research on
individuals with prostate cancer. Manual muscle testing was rated
2B, unable to recommend at this time due to lack of psychometric
support, and muscular endurance testing was not recommended
(1). Conclusions: Utilizing objective dynamometry for hand
grip and muscle strength testing provides precise measurement
to assess baseline status and monitor change among men treated
for prostate cancer.
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INTRODUCTION
Prostate cancer is estimated to be the most common form of
cancer in American men. After lung cancer, it is the leading cause
of cancer death among males.1 The American Cancer Society
estimates that approximately 221,000 new cases of prostate
cancer will be diagnosed in the year 2015 alone, and approximately 1 in 7 men will be diagnosed with prostate cancer during
their lifetime.1 Incidence rates of prostate cancer have changed
dramatically over the past 20 years; rapidly increasing from 1988
to 1992, declining sharply from 1992 to 1995, remaining relatively stable from 1995 to 2000, and again decreasing from 2000
to 2010.1 This unpredictable trend primarily reflects the change
in the utilization of prostate-specific antigen (PSA) blood testing
by health care providers for the detection of prostate cancer.1
Prostate cancer may be a fatal disease, but most men diagnosed
with prostate cancer do not die from it. The relative United States
5-year survival rate for all stages of prostate cancer is nearly
100%, while the 10-year and 15-year survival rates are 99% and
94%, respectively, with more than 2.9 million men still living.1
As the number of men living beyond a prostate cancer diagnosis rises, focus of care has broadened to include quality of life
(QOL) issues. Recent research provides evidence that the majority of cancer survivors have significant impairments that often go
undetected and/or untreated, and therefore may result in disability.2 Androgen deprivation therapy (ADT) is a common treatment
method for the early stages of prostate cancer. During the first
year of ADT, survivors of prostate cancer (PCS) often experience
a deficiency in sex hormones, insulin resistance, an increased
central/visceral adiposity, a decrease in bone density, lean muscle
mass, and whole body muscle strength.3 What is significant
for PCS is that the impairments can often be seen in the whole
body, rather than just the area treated for cancer. Prostate cancer
survivors receiving ADT had 40% less upper body strength
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than a group of non-ADT PCS and 22% less upper and lower
body strength than a healthy control group, and 27% reduction
in strength compared to a PCS non-ADT group.4 Strength is
reduced on isotonic testing such as chest press and leg extension,
isokinetic knee extension testing and isometric testing with grip
dynamometer.4-7 The long term effects of ADT persist over time
with a decrease in lean muscle mass.6 Adverse changes in muscle
composition may exacerbate normal sarcopenia, thereby further
impacting muscular strength and endurance as well as physical
function and independent living. The decrease in muscle mass
and subsequent strength is associated with impaired functional
mobility as indicated by increased times to complete a 5 repetition sit-to-stand test and 6 meter walk test.6,8
Diminished muscular endurance and fatigue are also increasingly recognized as a troublesome complaint among patients with
cancer.7,9 Cancer-related fatigue has been hypothesized to be both
a central phenomenon as well as a peripheral occurrence. Centrally mediated fatigue is thought to arise from the loss of voluntary activation of muscles due to processes proximal to the neuromuscular junction, while peripheral fatigue has been attributed
to failure of muscular contraction or metabolic changes within the
muscle.10 Muscular changes associated with ADT use can influence muscular endurance in PCS and have a significant negative
impact on QOL and patients’ self-care abilities. Researchers have
reported impairments among PCS to be as high as 24% for activities of daily living (ADLs) and 42% for instrumental activities of
daily living (IADLS).8 Among such patients, the prevalence of fatigue is generally reported to be greater than 65%.11 Furthermore,
complaints of diminished endurance and of fatigue persist beyond
the treatment timeframe.7,12,13
Impairments in strength and muscular endurance have been
linked to declines in independence, functional mobility, and subsequent QOL. Activities of daily living deficits, the use of an assistive device, and abnormal functional screen findings are associated with an increased risk of falling.7 Falls can lead to more
serious injuries such as an increased risk of fractures and hospitalizations, thereby decreasing the QOL and level of independence
for survivors.8 It is important, therefore, to accurately identify impairments in muscular performance in order to initiate early intervention to mitigate the effects of ADT and subsequent functional
decline among PCS.
In 2010, the American Physical Therapy Association’s
(APTA) Oncology Section created the EDGE (Evaluation
Database to Guide Effectiveness) Task Force to develop recommendations for outcome measures to be used when assessing the
status of survivors of cancer.14 This systematic review evaluates
the ways in which strength and muscular endurance are measured
clinically in individuals with prostate cancer. The reliability,
validity, minimal detectable change (MDC), and/or minimally
clinically important difference (MCID) are important psychometric properties that need to be evaluated to justify clinical use
of outcome measures.15 Tools used to track and measure patient
outcomes should be validated in the population in which they are
used to be most beneficial. Additionally, these tools need to be
assessed in light of clinical utility, including the availability of
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resources, cost, ease of use, and availability of normative data.
The purpose of this systematic review is to identify commonly
used methods of evaluating strength and muscular endurance in
PCS and to make recommendations of the best methods based on
psychometric properties and clinical utility.
METHODS
Search strategy
The authors systematically searched the literature for outcome
measures that directly measured strength and muscular endurance
to evaluate the psychometric properties and clinical utility of
such measures. The primary search was conducted in February
2014 in PubMed/Medline and CINAHL, with secondary searches
occurring through July 2014 using Web of Science, Ovid, Google
Scholar, Sports Discus, Cochrane Review, PEDro, and Academic
Search Premier. Search terms used alone and in combination
included: Prostate cancer or neoplasm and; strength measure/
measurement/test, muscular endurance measure/measurement/
test, manual muscle test, psychometric properties, clinometrics,
dynamometer/dynamometry, power, and energy, along with
the following MESH terms: “Muscle strength dynamometer”
OR “Muscle Strength” OR “Hand Strength.” Relevant articles
and journals focusing on orthopedics or fitness measures were
reviewed recursively for other potential studies. The prostate
cancer population took first priority within the search, however,
if no studies included this population, patients with other cancers,
geriatric patients, and the general population were considered for
review.
Included studies of tests of muscle strength and muscular
endurance had to report psychometric properties, present clinically feasible methods, have adults (preferably male) as participants, and be published in the English language. The publication
dates were limited to 1/1/1995 and after, as long as the inclusion
criteria were met. Studies were excluded if they focused on nonclinical measures of strength and muscular endurance, or were
functional mobility measures (eg, Timed Up and Go, sit-to-stand,
gait speed, etc.).
After completion of the literature search, relevant articles
were classified into 4 strength categories and one additional
category for muscular endurance. The 4 strength categories were:
manual muscle test (MMT), 1 repetition maximum (1-RM) testing, hand-grip strength (HGS) using dynamometry, and hand-held
dynamometry (HHD). These categories for strength measurement
tools were selected based on characteristics of each measurement
tool described in the available literature. Each outcome measure
was appraised by two reviewers independently using the Cancer
EDGE Outcome Measure Rating Form.14 Outcome measures
were then rated on the 1-4 Cancer EDGE Task Force Rating Scale
taking into consideration both psychometric properties and clinical utility (Figure 1).14 If an outcome measure rating was found
to be in disagreement between the two independent reviewers,
the disagreement was resolved by discussion with all 5 reviewers
until consensus was obtained. Finally, all articles reviewed for
an outcome measure were included in a reference section of the
EDGE form for each appropriate measure.
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4

Highly Recommend

3

Recommend

2A
2B
1

Unable to Recommend at
this time
Unable to Recommend at
this time
Do Not Recommend

Highly recommended; the outcome has good psychometric properties and good clinical utility; the measure has been used
in research on individuals with or post prostate cancer.
Recommended; the outcome measure has good psychometric properties and good clinical utility; no published evidence
that the measure has been applied to research on individuals with or post prostate cancer.
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure;
the measure has been used in research on individuals with or post prostate cancer.
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure;
no published evidence that the measure has been applied to research on individuals with or post prostate cancer.
Poor psychometrics &/or poor clinical utility (time, equipment, cost, etc.).

Figure 1. Cancer EDGE Rating Scale.

Identification

Figure 2. PRISMA flow of literature search.

# of records identified through
database searching: 680

# of additional records identified
through other sources: 3

Eligibility

Screening

Records after duplicates removed:
656

Articles screened for
eligibility:
656

Articles
excluded from
title and
abstract review:
574

Full-text articles
assessed for eligibility:
82

Full-text articles
excluded, with
reasons: 52

Included

Articles included in
qualitative synthesis: 30

One
Repetition
Maximum
Articles: 4

Muscular
Endurance
Articles:
0

Manual Muscle
Testing
Articles: 2

Hand-grip
Articles: 8

Hand-held
Dynamometry
Articles: 24

Figure 2. PRISMA flow of literature search.

Data Extraction and Synthesis
Relevant psychometric data, when available, were extracted
and recorded on the Cancer EDGE Task Force Outcome Measure
Rating Form for each study. This data included: intra-, inter-,
and test-retest reliability values, with confidence intervals as
available, validity, MDC, standard error of measurement (SEM),
and MCID. Reliability and validity were determined by either the
Pearson (r) or Intraclass Correlation Coefficient (ICC), or Kappa
values (K). Correlation coefficients of greater than 0.75 are
considered good to excellent, 0.5-0.74 moderate, and below 0.5
considered poor.16 Kappa values greater than 80% demonstrated
excellent agreement, 61% to 80% substantial agreement, 41% to
60% adequate agreement, and less than 40% showed poor agreement.16 Clinical utility was assessed using the criteria of: availability of resources, cost, ease of use including time necessary to
complete testing and clinician training, scoring and interpretation,
and availability of normative data for comparison.
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RESULTS
The initial literature search for muscle strength and endurance resulted in 683 articles. The titles were screened and any
duplicates removed by the assessors. Article titles and abstracts
were then reviewed to identify studies that specifically addressed
the purpose of this review. Eighty-two articles were retrieved
and assessed for eligibility. Thirty articles were included in the
study after exclusions were applied. Figure 2, the PRISMA Flow
diagram, details the literature search process.
By category, the number of articles reviewed were: MMT
= 2, 1-RM = 4, HGS = 8, and HHD = 24. No articles were
found which met inclusion criteria to assess muscular endurance
measures, although such tests have been used in prostate cancer
research. Note that some research studies evaluated multiple
tools, such that the number of articles for each category is not
mutually exclusive. Table 1 demonstrates the clinical usefulness
of strength and muscle endurance testing methods.
Two measures were recommended (rated 3) by the Prostate
Cancer EDGE Task Force members: HGS and HHD.5 These
measures are recommended for clinical use to objectify strength
measures. One repetition maximum testing was scored a 2A,
unable to recommend at this time, because of a lack of high clinical feasibility, although there is evidence of use in prostate cancer
research for chest and leg press strength assessment. Manual
muscle testing and muscle endurance were scored a 2B, unable
to recommend at this time, due to lack of psychometric support.
Muscular endurance testing lacks psychometric support and is
difficult to perform in a clinical setting, and was rated by the Task
Force as 1, do not recommend. See Table 2 for Task Force ratings
and clinical utility comments. Table 3 details the psychometric
properties of the clinical measures of strength.
DISCUSSION
The measurement of strength and muscular endurance in
men who have been treated with ADT for prostate cancer is
essential to the rehabilitation continuum. The effect of ADT on
muscular tissue is well documented,4-6 and the loss of strength
and muscular endurance impairs functional mobility6 and subsequent QOL.4,7 Therefore, valid and reliable measures of strength
and muscular endurance are critical for this population in order
to identify deficits, to establish a comprehensive picture of the
patient’s functional goals and needs, and to monitor progress
throughout the course of treatment and beyond.
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Table 1. Clinical Usefulness for Strength and Muscular Endurance Measures
Measure

Equipment Needed

Cost

Ease of Use

Scoring/Interpretation

Normative Data

MMT

No

Free

High

Easy

Yes*

1-RM

Yes – weights or machines

Minimal

Moderate

Easy

Inconsistent

HGS

Yes – dynamometer

Moderate

High

Easy

Yes

HHD

Yes – dynamometer

Moderate

High

Easy

Yes

Muscle Endurance

Yes – weights or machines

Minimal

Not established

Moderate

No

Abbreviations: MMT, manual muscle test; 1- RM, one repetition maximum; HGS, hand-grip strength; HHD, hand-held dynamometry
*Based on the rating of a 5 being “normal” strength.

Table 2. Prostate Cancer EDGE Task Force Ratings and Clinical Utility
Measure

Prostate Cancer EDGE
Task Force Rating

Clinical Utility

Hand-grip Strength

3

Equipment is easy to use clinically and staff training is simple. Good clinical utility.

Hand-held Dynamometry

3

Easy to use clinically; methodology similar to manual muscle testing. Normative data available.

1 Repetition Maximum

2A

Not often used clinically. Psychometric support is limited.

Manual Muscle Test

2B

Highly useful in the clinic, but poor psychometric properties do not support use.

Muscle Endurance

1

Not often tested clinically. Used in research, but lacks psychometric assessment.

Findings from this systematic review indicate that the
measurement of strength is best performed using objective dynamometry for both hand grip and extremity measures. No recommendations for the clinical measurement of muscular endurance
can be made at this time.
Strength
Accurate measurement of strength using dynamometry is
achieved through a method that is valid, reliable, and sensitive to change. Importantly, by quantifying force output as a
measure of strength, clinicians can measure strength objectively
to determine deficits, plan treatment, and measure progress.
Although used widely, MMT, which ranks strength on a 0-5 scale
(0 representing no muscular contraction and a 5 indicating full
strength),17 has limitations which need to be considered in light
of emerging affordable and clinically feasible alternatives which
provide greater validity and reliability. Manual muscle testing
is a subjective measure of strength. This is particularly true for
the antigravity grades of 3 or greater, which lend themselves
to personal interpretation of the evaluator. Although reliability
measures indicate that there is adequate intrarater consistency
within a single evaluator, the amount of force exerted by multiple
testers of a 3+ for the same participant are quite variable.18
Another important limitation to be considered is that the MMT
scale is ordinal rather than interval; the difference between a
muscle graded a 3 and one graded a 4 is not necessarily the same
as the difference between a 4 and a 5. This limitation in grading
and lack of precision of measurement does not allow the clinician
to accurately describe strength gains made through rehabilitative
measures, and generally lacks the sensitivity needed to appreciate
small gains in strength.
Tools which are considered accurate possess a small level of
error. The SEM of the two HHD examined in this review varies
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from 4.9-12.5N.19,20 One kilogram is equivalent to 2.2 pounds or
9.8N. With a SEM of no greater than 12.5N, the error of measurement in the HHD is less than 1.3 kg (2.9 pounds). The hand grip
dynamometers evaluated have a SEM of 0.76 – 1.25 kg.21 Any
amount of change in strength measures greater than the SEM, 1.3
kg, is real change. Research and analysis establishing the MDC
or MCID for dynamometry is slight, but studies reported MDC
values of 1.75-5.58 kg in cancer populations,20,22 and up to 7.3 kg
in a healthy population.19 What the actual amount of change in
force output that is clinically meaningful will vary depending on
the muscle group tested, the age and gender of the individual, and
the functional needs of that person. This clinically meaningful
change will require the judgment of the clinician.
The validity and reliability of HHD is well established in the
literature. These psychometric properties have been described for
multiple populations: healthy individuals, chronically ill, and
those with cancer.20,23-27 Overall, validity with strength measured
using isokinetic dynamometry is good to excellent.25,26 Although
reliability is reported as good to excellent in most studies,23,24,26,27
it can be improved through the use of a fixation method. Because
research shows that the tester gender, body weight, or grip
strength can influence the force values obtained using HHD,28
it is important to create a mechanism of consistent resistance.
Research supports using some external fixation for the dynamometer to improve the interrater reliability of dynamometry in a clinical setting. Studies have investigated different devices including
brackets,29-31 or straps.32,33 The studies whose psychometric properties are reported in this review did not use external stabilization,
and it is reasonable to conclude that reliability measures would
improve with this use. In a clinical situation, a mobilization belt
can be strapped around the dynamometer and fixed in opposition
to the force vector to provide a consistent resistance for maximal
voluntary contractions.
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Healthy Population:
ICC = 0.94-0.9847

Healthy Population: 30
Male examiners
(knee flex/ext)
ICC=0.79-0.93
(0.64-0.97)
Female examiners
(knee flex/ext)
ICC=0.88-0.91
(0.81-0.95)

Hand-grip
Strength

Hand-held
Dynamometry

Advanced Cancer:
ICC=0.8351

Cancer Population:
Pearson r=0.96
ICC=0.96 (0.92-0.98)20

Hip flex, knee ext, ankle DF = 0.76-0.94
(0.33-0.97)24

Critically Ill:
Knee ext = 0.78-0.79 (0.32-0.95)23

Healthy Population:
Knee ext = 0.91-0.97 (0.68-0.99)

Highest Score of 3 Trials
ICC= 0.82-0.9248

Mean of 2 trials:
ICC=.93-.9521
ICC=0.78-0.82 (0.65-0.89)49

Healthy Population:
ICC = 0.9948

Healthy Population:
Squat/Knee ext:
ICC=0.94-0.9644
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Knee ext, hip flex, ankle DF = 0.31-0.75
(0.17-0.87)
Sum Score = 0.83 (0.67-0.91)
Using Cohen’s kappa = .38
(0.44-1.0)

ICU Patients: 42
Knee ext, hip flex, ankle DF = 0.99 (0.97-1.00)
Agreement for detecting significant weakness =
1.00 (0.55-1.00)

Interrater Reliability (ICC)

Advanced Cancer:
ICC=0.9051

Knee ext
ICC=0.84-0.9526

Community-dwelling
Older Adults:
Hip abd/flex; knee ext
ICC=0.88-0.9452

Critically Ill:
Knee ext = 0.89-0.92
(0.69-0.97)23

Healthy Population:
Knee ext = 0.96-0.97
(0.85-0.99)

Advanced Cancer Patients:
Spearman’s rho =.09750

With Gait Speed:
r=0.79-0.8326

Cancer Pop (with a pull-gauge):
2.02 kg (+/- 3.96)20

Critically Ill:
5.7-7.1 kg23

Healthy Pop:
.57 – 1.2719
6.5-7.3 kg23

Minimal Detectable Change:
Cancer Pop:
5.59 kg20
1.75-2.77kg22

With TUG:
r=-0.71-0.86

HHD with Biodex:
r=0.9125

Advanced Cancer
Patients:
%CV as a measure
of precision = 6.350
%CV=10.5911.6151

Validity

Standard Error of Measure:
Healthy Pop:
5.5-6.9 kg23
Critically Ill:
2.1-2.6 kg23

Standard Error of Measurement
Older Adults in Care
0.76 – 1.25 kg.21,48

Type 2 DM (using est 1-RM):
1.24-3.5646

Type 2 DM
Leg press/knee ext:
0.98-0.99
(0.95-0.99)46
Community-dwelling
Older Adults:
ICC = 0.94-0.9826

Standard Error of Measurement
Healthy Population:
Squat/Knee ext:
3.2-13.144

Responsiveness to Change

Healthy Untrained
Population:
Leg press/knee ext:
ICC=0.97-0.9945

Test/Retest Reliability
(ICC)

Hand-held dynamometry
has good psychometric
properties and clinical
utility; it has been tested
in healthy patients and
advanced cancer patients,
but not tested in individuals with prostate cancer.

Hand-grip strength has
good psychometric properties and clinical utility; it
has been tested in healthy
patients and advanced
cancer patients, but not
tested in individuals with
prostate cancer.

Good psychometric values,
however, clinical utility
makes this measure difficult to use. Time consuming to perform, and if done
on equipment, expensive.

Easy to do with no equipment required; interrater
reliability highly variable.
Validity not established
outside of neurological
population.
Not used in prostate cancer
population.

Clinical Utility

Responsiveness (Effect Size):
Lower extremity strength using multiple
devices/
populations: ~0.40-1.053
Abbreviations: ICU, intensive care unit; flex, flexion; ext, extension; abd, abduction; pop, population; DF, dorsiflexion; ICC, intraclass correlation coefficient; r, Pearson’s correlation coefficient; SEM, standard error of
measurement; MDC, minimal detectable change; MCID, minimally clinical important difference; DM, diabetes mellitus; HHD, hand-held dynamometer; 1-RM, 1-repetition maximum; CV, coefficient of variation; TUG,
Timed Up and Go; kg, kilograms

Healthy Population:
Squat/Knee ext:
ICC=0.64-0.9044

Intrarater Reliability
(ICC)

1-RM
Testing

Manual
Muscle
Testing

Measure

Table 3. Psychometric Properties of Strength and Muscle Endurance Methods or Tools

Sensitivity to change is impacted by the tool used, as well
as the unit of measure for that tool. Manual muscle testing lacks
properties of measurement which are sensitive. Force is often
measured by Newtons (N), pounds (lb), or kilograms (kg). The
unit of force output for MMT remains an ordinal number whereas
the output on dynamometers is in pounds or kilograms. Muscles
graded a 4 may have as little as 10% of the maximum strength of
a muscle.34 Hand-held dynamometry uses a unit of measure that
is an interval scale; the amount of difference between a 3 and a
4 is the same as between a 4 and a 5. Sensitivity to change over
time can then be accurately described. Furthermore, clinicians
consistently evaluate patient performance against an expected
normal level of performance. Use of HHD allows this comparison
to be made as normative values have been established for human
strength measures. Although outside the scope of this paper, the
reader is encouraged to reference the numerous studies reporting
these values.35-37
Measurement of strength is most accurate using dynamometry. The use of dynamometry in the prostate cancer population
is limited to two smaller studies20,22 which used a strain-gauge
rather than a force gauge typically seen clinically. This limited
the authors’ ratings of HHD and HGS to a 3 (recommended)
in this review, however, both HGS and HHD offer the clinician
a clinically feasible method to measure strength that has the
necessary psychometric properties to support good validity,
reliability, MDC, MCID, and sensitivity to change, and have
been used in other cancer populations. The use of 1-RM cannot
be recommended secondary to low clinical utility and weaker
psychometric properties.
Muscular Endurance
Clinically feasible methods of measuring muscular endurance with accompanying sound psychometric properties and
normative values remain elusive. Because of this, muscular
endurance, the ability to sustain force output over time, is seldom
assessed in a clinical setting. Yet understanding overall muscular
fitness after treatment with ADT is an important consideration
given the effects of ADT on muscle tissue, including sarcopenia.38 A component of muscular fitness is muscular endurance.
Research is emerging suggesting that muscular endurance is
lower in men treated for prostate cancer with ADT.7,9 Therefore,
finding appropriate means to assess this clinically is important for
monitoring patient status.
The most available method to measure muscular endurance
is some variation of a repetition to failure loading test. An early
study examining muscular fitness among men treated with ADT
compared a group engaged in a resistance exercise program to
a group without exercise using a fixed load repeatedly lifted at
a standard rate, and counted the number of repetitions correctly
completed.7 Findings from this study showed an increase in
the number of repetitions after 3 months of resistance exercise
training, with an accompanying decrease in self-reported fatigue
using the Functional Assessment of Cancer Therapy – Fatigue.7
Another study recorded the number of repetitions of 70% of 1RM
lifted until failure comparing a group of men on ADT to a group
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of healthy controls. This study found no differences between
groups for muscular endurance repetitions to failure using 70%
of 1 RM.6 To better understand the implications of these results,
it is important to examine how muscular endurance should be
measured.
The American College of Sports Medicine recommends that
lifting 40-60% of a maximum resistance repeatedly in training
will increase muscular endurance.39 Intuitively, then, measuring
endurance should be completed using repetitions to failure of
40-60% of 1RM. Neither study purporting to measure muscular
endurance utilized this method, although findings that an increase
in repetitions suggest an increase in muscular endurance among
men using ADT. The limitation to this study was the lack of
a healthy control comparison to determine whether deficits in
muscular endurance were present at baseline.
Measuring muscular endurance with a repetition to failure
using 40-60% of 1 RM is not without merit. Establishing a
baseline measure for an individual is possible, and repeating the
measure postintervention can inform change. The limitation of
this methodology is the lack of normative data for age, gender,
and muscle group. Such data is difficult to gather, as the number
of repetitions to failure is largely dependent upon the muscle
mass of the individual.40
What is needed is a test for muscular endurance which
possesses good clinical feasibility, along with strong psychometric properties. Isokinetic dynamometry offers a more reliable and
valid method to measure muscular endurance, but lacks clinical
feasibility. However, a study of muscular endurance using a
Biodex stationary dynamometer, measuring maximal voluntary
isometric contraction (MVIC) levels pre- and post-endurance
activity, shows promise.41 Findings from this study suggest that
rather than measuring repetitions to failure as a unit to quantify
endurance, perhaps measuring MVIC pre- and post-activity may
provide a more reliable and valid method to measure endurance.
It may be possible that using HHD to measure MVIC before and
after some fatiguing activity holds promise for a more clinically
realistic measure of muscular endurance. At this time, measuring
muscle endurance clinically is not feasible and this systematic
review does not support it.
Further investigation is needed in designing a clinically
feasible, reliable, valid, and standardized method to measure
muscular endurance. A clinical method of measuring muscle
endurance should utilize the guiding principles of 40% to 60% of
maximum resistance lifted over time. The clinical method should
also be responsive enough to detect differences between healthy
and injured tissue, as well as have a reliable and quantifiable
normative unit of measure.
Other research in cancer outcome measures should focus on
the specific needs of the population. More studies with men who
have been treated for prostate cancer examining reliability and validity as well as responsiveness to change are needed to determine
intervention effectiveness. Cutoff scores should be established
to assess the severity of impairment and functional limitations.
Tools for specific practice settings across the continuum of care
need to be explored; it is reasonable to believe that responses of
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individuals will vary based on whether they are in the acute stage
of recovery or a more long-term stage, as the impact of treatment
changes with time.
CONCLUSION
Psychometrically strong and clinically feasible outcome
measures need to be utilized in evidence-based practice of
physical therapy. Measuring strength and muscular endurance
precisely in men with prostate cancer allows clinical decisionmaking to accurately identify impairments in body structures
which may impact activity and participation. Both HGS and
HHD are recommended as valid and reliable methods to assess
strength in PCS. No clinical measures for muscle endurance
could be recommended at this time. Further research is necessary
to devise a clinically feasible muscular endurance test with sound
psychometric properties for clinical use in this population.
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ABSTRACT
Background: Multiple agencies have recognized the increasing care demands and the associated costs of a growing aging
population with incurable or life-threatening conditions, including cancer. Although the core concepts of physical therapy
(PT), cancer survivorship and palliative care (PC) appear to
be congruent and complimentary, there is little evidence in the
literature demonstrating a consistent role of PT in these settings.
This article will outline a care philosophy to use for educating
PTs, patients/clients, interdisciplinary team members, and as a
guide for PT care for the longitudinal management of the patient
with a cancer diagnosis, incurable illness, or a life threatening
illness. Methods: Literature review and perspective regarding
PT within cancer survivorship, PC and chronic disease management in the context of healthcare reform to provide a perspective
of the PRevention, Intervention, and Sustained wellness Model
(PRISM) care philosophy. Discussion: The PRISM promotes the
longitudinal management by the physical therapist for a patient
with a number of long-term conditions, including cancer survivorship, chronic disease or life threatening illness and its side
effects. Prevention includes primary, secondary, and tertiary
prevention in the presence of a disease. Intervention is generally
considered conventional or traditional physical therapy, while
Sustained wellness incorporates concepts related to maintaining health or slowing the decline of a progressive illness, injury
prevention, and anticipation and management of potential medical crises. Conclusion: The PRISM may have utility to guide and
educate care providers on PT’s role in managing individuals with
these conditions.
Address correspondence to: Reyna Colombo (rcolombo@
beaumont.edu) or Christopher Wilson (Christopher.wilson@
beaumont.edu); Beaumont Health System, Rehabilitation
Services, Suite 203, 44201 Dequindre, Troy, MI 48085, Ph:
(248) 964-4014, Fax: (248) 964-8099.

Rehabilitation Oncology
Vol. 33, No. 2, 2015

Key Words: side effects, prevention, navigator, wellness,
prospective
INTRODUCTION
Palliative care (PC) and physical therapy (PT) are congruent with similar treatment philosophies, including anticipating
and mitigating predicable and unforeseen medical events, optimizing and maintaining quality of life (QOL) in the existence
of a disease process or impairment, and supporting the patient
holistically.1 Despite these similarities, many physical therapists
(PTs) who work with patients with a chronic disease or a lifethreatening illness are not aware that they are in essence, and in
reality, providing a component of PC. Palliative care, while a
relatively new term to many practitioners, is the holistic, longitudinal management of an individual with a chronic, life threatening, or incurable illness.2 Cancer survivorship and QOL concepts
are closely tied to the care philosophy of PC and cancer survivors
note that QOL is a high priority throughout the survivorship
journey, of which PT has the potential to play an important role
across the spectrum of the disease process and treatment of side
effects.3 For example, chemotherapy treatment is associated with
pain, fatigue, weakness, and the magnitude of symptoms directly
affected QOL.4 Rather than focusing on the clinical aspects of
patient management for the patient with a life threatening illness,
this critical review of the literature and perspective paper examines various aspects as it relates to how cancer survivorship and
PC treatment philosophy are congruent with the overarching
concepts of health care reform. This literature review examines
how PTs and PT practice is best positioned to assist in meeting
the goals of cancer survivorship and PC through the PRISM care
model.
Health care reform and the Affordable Care Act, despite its
political controversy, brought to light the need for better management of life-threatening diseases and chronic illness in the interest of cost-effectiveness and quality outcomes. Some of the core
concepts of this management include:
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n  improved access to care,
n  earlier management,
n  preparation for medical emergencies and events,
n  holistic support of the patient and family, and
n  an integrated care team.
Reported benefits of this improved management include:
n  the possibility for improved functional capacity,
n  improved longevity,
n  reduced medical costs,
n  reduced stress to patients and caregivers, and
n  the patient’s active participation in their disease management
and medical care.5
Despite the congruency and compatibility of the PT and PC
philosophies, no articles were located that demonstrate strong
evidence that PT had achieved full integration into care teams
or were consistently consulted. This lack of evidence outlines a
research opportunity to provide evidence for the role of PT within
PC to best determine where PT principles may be applied with
the most benefit to the patient, the profession, and to society at
large. The purpose of this review is to outline the PRISM care
philosophy and provide a perspective as to the future role and
opportunities that the physical therapist is optimally positioned
to provide. PRISM is a care philosophy and educational tool to
assist PTs and other stakeholders in understanding PTs role in the
management of the cancer survivor or the patient with chronic
disease or life-threatening illness. This perspective is provided
in the context of a literature review highlighting issues related
to the aging population, the disproportionate health care costs of
this patient population, especially nearing the end of life, and the
focus on reform of the healthcare system. These factors provide
a significant opportunity for PTs to provide resources to manage
these patients.
METHODS
The key databases examined in the literature review included
the APTA’s Open Door portal, PEDro database, CINAHL, and
Google Scholar from 2003 to 2013. Key terms searched included
“physical therapy,” “palliative care,” “chronic disease,” and
“health care reform”/“affordable care act.” Six articles were
selected that best outlined the core concepts of the objectives of
this review. Although research articles were preferred as well as
articles published within the past 10 years, the sample of research
articles providing information related to the topic of PT involvement in PC in the context of healthcare reform were relatively
limited. This prompted utilization of some meta-analyses, position papers by think-tanks, and expert opinion medical manuscripts on the topic, as this level of articles is more common and
applicable to this review.
RESULTS
In a systematic review by Meier entitled, “Increased Access
to Palliative Care and Hospice Services: Opportunities to
Improve Value in Healthcare,” PC services were examined in the
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context of public health policy.6 Meier clarified the definition of
PC to provide best-possible QOL for patients and family caregivers, work in an interdisciplinary and community-based fashion to
promote seamless models of care across a range of settings. A key
aspect of PC is that “ideally PC should be initiated concurrently
with a diagnosis of serious illness and at the same time as curative
or disease modifying treatments.” A MedPAC report from 2010
that found that “10 percent—of the sickest Medicare beneficiaries
accounted for about 57 percent of total program spending, which
was more than $44,220 per capita per year,” with the costliest
individuals being those with a chronic disease.6 In a 2010 article
by the federal Office of Assistant Secretary for Planning and
Evaluation, individuals with a life-threatening illness or chronic
disease and their associated conditions and functional impairment
constitute about 10% of all patients in the United States (US),
but account for well over half of the nation’s health care costs.6
Meier found 15 articles that provided evidence that PC programs
positively affected “physical and psychosocial symptoms, family
caregiver well-being, bereavement outcomes, and patient, family,
and physician satisfaction.” A few studies noted that PC treatment
philosophies may even be associated with a prolongation of life.
Meier highlighted an article by Morrison et al in 2008 describing a net per-patient savings of $2,659. Common barriers to PC
include variable access, inconsistent services (especially in rural
areas), and an inadequate workforce with expertise in PC.6
In a white paper outlined by the RAND Corporation entitled,
“Living Well at the End of Life,” Lynn and Adamson discussed
the issue of aging baby boomers, which will significantly add
to the demand upon healthcare resources.7 By the year 2030, 9
million Americans who were born in the 1950s will be reaching
85 years of age and are likely to face significant disability.7 When
living with a life-threatening illness, a disproportionate amount of
health care costs are concentrated in the last several weeks and
months of life. Nine out of 10 people who die have a chronic lifethreatening illness including cancer, cardiac, respiratory illness,
dementia, and stroke. About 25% of those with chronic illness
may experience disability from their condition at any one time.
Three different common scenarios of chronic, life-threatening
illness were outlined:
1. “ Short period of evident decline” which is typical of cancer.
In this case, there is a longer term preservation of comfort
and function until the disease process becomes overwhelming
to the systems, then a steady, rapid decline in function may
occur.
2. “Longer term limitations with intermittent exacerbations and
sudden dying.” This is more common with organ system
failure pathologies such as COPD and CHF.
3. 
“Prolonged dwindling.” This is more typical of central
nervous system failure that is generally of a slow decline
where institutional long-term care facilities are beneficial.
Based on these descriptions, methods to innovate and reform
care for these chronically ill adults were recommended, including
integrating care across settings, quality improvement programs for
Rehabilitation Oncology
Vol. 33, No. 2, 2015

pain management, advanced directive planning, and PC consultations. Some longer term suggestions by the RAND Corporation
include addressing the shortage of caregivers, reforming federal
finance policy, evaluating the cost-effectiveness of treatments,
re-evaluating life possibilities for dementia (having the person
make life choices before decisional capacity is absent), and an
emphasis on strategic planning. These recommendations help lay
the framework for what gaps PTs may fill in the realm of PC and
chronic disease management.
The Agency on Healthcare Research and Quality (AHRQ)
performed a meta-analysis entitled, “Palliative Care for Adults”,
to analyze the evidence related to practice recommendations and
clinical guidelines for PC practitioners.8 The quality of evidence
and strength of recommendations were categorized to provide
the reader with improved information to provide evidence-based
best practices in PC. Some of the highlights of the findings
included that planning for PC should begin relatively soon after
diagnosis of a life-threatening illness. Emphasis was on the physical symptoms of a disease causing suffering and that controlling these symptoms should be a priority of PC practitioners.
Communication with patients and families was a critical component to set realistic goals, but provide realistic hope. The authors
provided additional evidence that PC was compatible, and not
mutually exclusive, with all other medical treatments, including
curative measures. Even after the patient’s death, the healthcare
team plays a key role in the grief and bereavement process. When
discussing which patients would be appropriate candidates for
PC, considerations include disease progression with functional
decline, pain or symptoms not responding to treatment, and a
need for advance care planning. Functional decline and pain
control are two categories of interventions that PTs may be able to
assist in the management of. The AHRQ document listed several
diagnoses that may prompt PC consideration including “debility/failure to thrive, cancer, heart disease, pulmonary disease,
dementia, liver disease, renal disease, and neurologic diseases
such as stroke, Parkinson’s, amyotrophic lateral sclerosis (ALS),
and multiple sclerosis (MS).” Several neuromuscular, musculoskeletal, cardiopulmonary, and neoplastic conditions are within
the scope of PTs practice.
An important component to determine the needs of the
individual with PC or with a life-threatening illness is the
ability to quantify and predict the level of disability, extent of
disease, and possibility of death. An article by Lau et al entitled,
“Use of Palliative Performance Scale (PPS) for End-of-Life
Prognostication in a Palliative Medicine Consultation Service”
was a prospective analysis of 513 patients evaluated by a British
Columbia PC team.9 The PPS as described by Wilner and Arnold
evaluates 5 observer-related domains to rate a patient in various categories to attempt to describe the level of disease and to
identify and track potential care needs of PC patients.10 The 5
categories included:
n  Ambulation;
n  Activity level;
n  Evidence of disease;
Rehabilitation Oncology
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n  Self-care, intake; and
n  Level of consciousness.
Besides the evidence of disease component, all components
are consistently evaluated by PTs as a regular part of their scope
of practice. Lau et al report that initial PPS scoring is a significant
predictor of survival, challenges are present due to the “ambiguity and difficulty when assessing patients at higher PPS because
of the subjective nature of the tool.”9 This tool and its potential
usefulness in predicting survival rates may be useful to PTs who
are working with individuals facing life-threatening illness in
various stages of disease progression. This may provide PTs with
improved data on anticipated lifespan and may assist in improved
activity prescription and anticipatory equipment prescription for
future disease progression.
When shifting focus more specifically toward PT involvement within PC, a key finding in a manuscript based on expert
opinions was that “Rehabilitative services are underutilized in the
PC setting, and more research is needed to address how patients
may benefit as they approach the end of their lives.”11 The role
of rehabilitation in PC is described and the evidence for the
benefit of rehabilitation for several major diagnoses reviewed.
With regard to PT, 3 facets of PT in PC were outlined: (1) Direct
patient care, (2) Educating the patient, family, and caregivers, and
(3) Functioning as a team member within the interdisciplinary
group. In addition to the physical benefits provided, the authors
discussed the psychological benefit of PT, including several citations providing evidence for a reduction of psychological suffering when participating in rehabilitation in patients with terminal
cancer. In later stages of disease progression, this reduction
in psychological distress and suffering may outweigh physical
gains and pain reduction that the PTs may be intending to treat.
Specific disease conditions and the clinical indications for treatment were described including ALS, advanced dementia, chronic
heart failure, COPD, and outlined specific treatment regimens.
Some limitations to rehabilitation and PC described included
infrastructure of the medical system not supporting the utilization or cost-effectiveness of PT within PC. In addition, functional outcome measures were advocated, such as the Palliative
Performance Scale.10
Palliative Care and Management Principles in Older
Patients with Advanced Chronic Obstructive Pulmonary Disease,
a systematic review by Yohannes, a physiotherapist in the
United Kingdom examined the care principles for end stage
COPD.12 Psychiatric disorders, in addition to dyspnea from the
disease process, are a significant issue. With regard to dyspnea
management for this patient population, as expected, this was
a key symptom that required management and reported as 90%
prevalence of dyspnea at rest or minimal exertion with end stage
COPD as compared to end stage CHF with 60%.12 Application of
a fan pointed in the direction of the face displayed early evidence
of reducing the symptoms of dyspnea, in addition to commonly
utilized medical treatments including supplemental oxygen and
medications. Fatigue was a common symptom noted by nearly
all patients. Yohannes recommended applying a fatigue rating
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scale such as the Manchester COPD Fatigue Scale. This scale is
valid and reliable in quantifying fatigue. Pulmonary rehabilitation displayed evidence of reducing and controlling fatigue in this
patient population.12 Specifically, home-based physical rehabilitation was useful in maintaining physical functioning in advanced
COPD. Finally, unlike late stage cancer, patients with COPD are
less likely to have access to or be aware of PC services, creating
a health disparity in this underserved population.12
PRevention, Intervention, Sustained wellness Model (PRISM)
Care Philosophy
The PRISM care philosophy encapsulates and summarizes
multiple concepts of chronic disease management. The intention of the PRISM care philosophy is to provide an educational
tool and guiding care philosophy toward care of the patient
with a chronic disease or life-threatening illness (Figure 1). The
PRISM may be employed to increase the awareness, understanding, and communication of the varied roles that PTs offer in the
management of the cancer survivor or patient with a chronic or
life-threatening disease. The visual representation of a spectrum
provides illustration of the relative continuum of roles that PT is
able to offer, as opposed to a dichotomous perspective of “PT or
no PT.” This spectrum provides for an illustration of a variety of
different involvement levels for the physical therapist from an
annual check-up with a PT in the early stages of a newly-diagnosed disease through early intervention for an impairment or
functional imitation, all the way through providing psychosocial
support and comfort measures at the transition to hospice care.
To illustrate the clinical applicability and utility of the PRISM
care philosophy, the 3 core concepts of Prevention, Intervention,
and Sustained wellness are summarized with patient examples.
These examples are not meant to be all-inclusive, only to highlight common opportunities that PTs may apply each phase of the
PRISM care philosophy.
Prevention. Preventative care, a growing area of physical
therapist practice, is not commonly considered in the presence
of an already diagnosed incurable illness. Physical therapist care
in the realm of prevention may take multiple forms in chronic
disease. A common consideration of primary prevention is the
initial education in avoiding at-risk behaviors, such as poor diet
or smoking, or encouraging disease-preventing behaviors, such

Figure 1. PRISM visual depiction.
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as exercise and advocating for appropriate cancer screenings.
In conditions such as COPD and CHF, a periodic or annual
re-evaluation and exercise or activity prescription may be
appropriate to maintain strength and functional capacity. These
periodic re-evaluations (prospective surveillance) may be able
to establish baseline functional levels and identify an early exacerbation of a disease process and prompt further management as
appropriation. Prevention in an acute or in-patient setting may
include prospective screenings by PTs of all patients within a
specific nursing unit to provide early identification and treatment
of potential rehabilitation needs before several days of bedrest
causes unwanted medical sequelae.
Intervention. The intervention phase of the PRISM philosophy is what is commonly considered by interdisciplinary team
members, patients, and some PTs as traditional or conventional
PT. Although this is what is commonly known as PT, there is
perceived to be an underutilization of traditional PT services in
the presence of a cancer diagnosis, chronic disease, or other lifethreatening illness. A portion of this underutilization may be the
perception that in order for traditional PT to meet the tenets of
medical necessity, reasonable progress must be made. As many
chronic or life-threatening illnesses require the skill of a physical
therapist to maintain or slow the decline of function or impairments, conventional intervention-based PT may be indicated.
This point was clarified in the US Supreme Court case Jimmo
vs Sebelius that ruled rehabilitation services may be applicable
and medically necessary to maintain or slow the decline of the
functional status of a patient with a degenerative illness or an
incurable condition.13 This may include concepts such as cancer
rehabilitation or impairment-based interventions for side effects
of treatments or surgical procedures. This may also include
intervention-based treatments for conditions such as pelvic floor
rehabilitation for genitourinary cancers.
Sustained wellness. The last concept entails the relatively
stable period after an exacerbation or a change in an incurable
or chronic condition where a certain level of activity, exercise,
or health maintenance behaviors are required or beneficial to
maintain an optimal level of activity and participation and allow
the patient/client to enjoy the highest level of QOL for as long of
a duration as possible. In the absence of these Sustained wellness
activities, a patient’s condition may worsen; however, within the
Sustained wellness phase, skilled PT may not be medically necessary, feasible, or appropriate. An example of this is a facilitated
exercise regimen provided by an exercise and wellness program
for cancer survivors in active treatment and who prefer supervision, guidance, or encouragement with a prescribed exercise
regimen. This may include a cancer survivor who has achieved
remission or cure but is still working through after effects of
chemotherapy, radiation, or surgical intervention, or an “aftercare” program for patients with residual deficits after a stroke
to maintain a certain level of functioning when their recovery
has stabilized and their care no longer meets medical necessity
for physical therapist services. These after-care programs may
begin with an exercise prescription for a certain level of activity
from a physical therapist and facilitated by a healthcare or exerRehabilitation Oncology
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cise professional with training in the medical condition and the
complexities of the condition. In the Sustained wellness phase,
the physical therapist may provide a consultative or supportive
role with periodic re-evaluations to monitor, correct, or progress
an exercise prescription.
DISCUSSION
Based on the literature review, the PRISM care philosophy
and the philosophical compatibility with cancer survivorship
and PC, several key outcomes should be pursued to assist in PTs
managing the patient with a cancer diagnosis, chronic disease,
or life-threatening illness. These are discussed in the context of
the APTA’s Position Statement passed by the House of Delegates
in 2011 entitled THE ROLE OF PHYSICAL THERAPY IN
HOSPICE AND PALLIATIVE CARE HOD P06-11-14-11.14
“Resolved, The American Physical Therapy Association
(APTA) endorses the inclusion of the following concepts in
hospice and PC:
n  Continuity of care and the active, compassionate role of PTs
and physical therapist assistants in hospice and PC.
n  Respect for the rights of all individuals to have appropriate
and adequate access to physical therapy services, regardless
of medical prognosis or setting.
n  An interdisciplinary approach, including timely and
appropriate physical therapist and physical therapist assistant
involvement, especially during transitions of care or during a
physical or medical change in status.
n  Education of PTs, physical therapist assistants, and respective
students in the concepts related to treating an individual while
in hospice and PC.
n  Appropriate and comparable coverage and payment for
physical therapy services for individuals who have transitioned
to hospice or PC in all clinical settings.”
Each component of this position is examined as to the PT
profession’s capacity, opportunities, and limitations in achieving
each of these tenets.
Continuity of care and the active, compassionate role of PTs
and physical therapist assistants in hospice and PC.
In this tenet, an emphasis is placed on the continuity of
care with the PTs. Currently PTs and PTAs are well-educated
in compassionate care in a more episodic manner of care with a
clear “evaluation” and “discharge” with the hope of a successful
discharge to where the physical therapist will deem a treatment
session “successful” when the patient does not have to return to
the care of the physical therapist. Although this thought process
is changing, it is changing in a slow manner and is incompatible
with the care concepts of PRISM and chronic disease management. The management of the individual with a life-threatening
illness and chronic disease requires a more longitudinal management of patient care that may require periodic re-assessment,
early identification of disease progression, anticipation of crisis
events or medical exacerbation, and some periods of convenRehabilitation Oncology
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tional intervention-based PT management. The APTA endorses
positions that highlight this model of care, including endorsement of an Annual Visit with a Physical Therapist and Physical
Therapist of Record and “Hand Off” Communication.15,16 These
positions provide examples of the PRISM concepts of prevention,
early identification, and continuity of services. It is recommended
that future professional education incorporate these concepts
into curricula. A suggested emerging role of a physical therapist
is that of a “rehabilitation navigator,” with analogous structures
to an attending physician or nurse navigator. This rehabilitation
navigator would coordinate care of a variety of rehabilitation
professionals throughout the disease process and maintain a
long-term relationship with the patient. In addition to providing
components of disease-specific treatment, the navigator would
assist in symptom monitoring as well as facilitation and consultation of specialist PTs who focus in one area of specialty, while
the therapist navigator provides for longitudinal management and
coordination of care throughout the disease continuum.
Respect for the rights of all individuals to have appropriate
and adequate access to physical therapy services, regardless of
medical prognosis or setting.
This objective of the APTA’s position on the role of PT in
hospice and PC focuses on both ends of the disease spectrum,
touching on the awareness and referral process requirements
among all stakeholders as to the PTs role in management in
Prevention, early Intervention, and Sustained wellness across the
continuum of care.17,18 Some patients may not understand the role
of exercise, prevention, wellness behaviors, and early intervention
that a physical therapist may offer, especially in the presence of
chronic or life-threatening illness. The health care team members
who are commonly considered referral sources for PTs, including physicians, mid-level providers, nurse navigators, and social
workers, may not have increased awareness of the role of PT in
the continuity of care beyond conventional PT care. Historically,
the APTA has endorsed improving access to PT services through
legislative efforts including direct consumer access, especially as
it relates to wellness services. As an example, Michigan was the
most recent, and 50th state in the US, to obtain direct consumer
access effective January 2015. The legislative rules did place a
time limitation on conventional PT visits, but no visit limits on
wellness or preventative visits to the PT services.19
An interdisciplinary approach, including timely and appropriate physical therapist and physical therapist assistant involvement, especially during transitions of care or during a physical
or medical change in status.
In an unpublished doctoral dissertation by Wilson entitled,
“Perceptions of PTs Regarding the Role of Physical Therapy
Within Hospice and Palliative Care in the USA and Canada: A
Qualitative Study”, a common theme noted by the participants
in the study was the importance of integration into the care team
to provide an interdisciplinary approach to patient management.
There was wide variability and frequent inconsistencies to physical therapist involvement into the Interdisciplinary Team (IDT)/
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Interdisciplinary Group (IDG). This emphasizes the importance
of continuity of services and hand-off of care described in the
APTA position when a patient transfers form one setting to
another and that the physical therapist of record should provide a
comprehensive description of the overall care philosophy of the
patient, recommendations for provision of treatment, precautions,
contraindications, and individual patient preferences.16 Several
examples of this hand-off of care includes transition to and from
home into hospitalization, discharge from sub-acute rehabilitation or in-patient rehabilitation into the home setting, and transition from outpatient therapy to a cancer survivorship exercise
program to wellness or monitoring settings, to name a few.
Education of PTs, physical therapist assistants, and respective
students in the concepts related to treating an individual while
in hospice and palliative care.
In promoting and proliferating the PRISM role of PT within
cancer survivorship, PC and chronic disease management, emphasis is placed on the potential circumstances that PTs and PTAs
may be self-limiting their own involvement in cancer survivorship, chronic disease management, and PC services. The authors’
clinical observations note that PTs and PTAs lacked awareness
of their role or potential role in the longitudinal management of
a cancer survivor or the patient with a chronic or life-threatening
illness. This lack of understanding of the role of PT within cancer
survivorship or PC among PTs and PTAs may cause hesitation
among referring physicians or practitioners, even those who are
strong advocates of the role of rehabilitation professionals in
management of their patients. The evidence of PT within cancer
survivorship and PC is continuing to grow; however, a slow transition is expected toward educating PT/PTAs in this role as much
of the institutional practice changes have historically occurred
through professional education as opposed to post-professional
education. Although forward-thinking programs may be adopting
cancer survivorship, chronic disease management, and PC principles into curricula, it may take an external credentialing body
like CAPTE (Commission on Accreditation of Physical Therapy
Education) to successfully drive more widespread change.
Appropriate and comparable coverage and payment for physical therapy services for individuals who have transitioned to
hospice or PC in all clinical settings.
Another administrative barrier to this care setting is that
current payment structures that do not consistently pay for PT
services in direct access, self-referral environments, or near the
end of life. The Medicare Hospice per diem rate is noted as a
potential limiting factor in PT provision in the end of life care.
One added benefit of PC services that creates significant practice
opportunities for PTs, is most insurances cover PC services in
the same payment structure that they cover traditional PT care.
The APTA is creating an Alternative Payment System working with the American Medical Association and the American
Occupational Therapy Association to update the PT CPT codes.20
This new billing, coding, and payment model better positions the
PT profession to provide an improved spectrum of care, especially
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in the interest of wellness and prevention models to better capture
the skills of PT in the context of PRISM. This important step to
improve support and access to PT includes properly reflecting
the decision making capacity of PT as a consultative service as
compared to a time-based, intervention-oriented service.
CONCLUSION
The PRISM philosophy incorporates several professional PT
positions and encapsulates current evidence on cancer survivorship, management of chronic conditions, and longitudinal care of
terminal or life-threatening illness and may have utility to guide
and educate care providers on PTs role in managing individuals
with these conditions. These core concepts are visualized in the
PRISM care philosophy and are outlined in the APTA’s position
on hospice and PC are not just localized to patients within PC
or even those with a chronic disease or a life-threatening illness.
These concepts are a philosophical evolution of the profession
of PT from an episodic, intervention-based practice, toward a
primary care service that incorporates all aspects of participation
in life events across the entire spectrum with a focus on QOL. To
achieve these lofty goals, the physical therapist and profession
must advocate for appropriate policy, education, and payment
structures for PTs of the future to manage these individuals in a
longitudinal manner.
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